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CHAPTER 1
INTRODUCTION
Despite the availability of powerful immunosuppressive agents, rejection
of the allografted heart remains one of the major problems associated with
cardiac transplantation. The inflammatory process in response to alloantigen is
in part due to the production by different cell types of soluble endogenous
mediators, including both cytokines and granzymes. The studies contained
within this dissertation were designed to further understand the
pathophysiological mechanisms involved in cardiac allograft rejection by
examining the production of these cytotoxic mediators. Specifically, detection
and quantitation of the cytotoxic products tumor necrosis factor-a (TNFa) and-~
(lymphotoxin, (LT)), and the T cell proteases, granzymes A and B (Hanukkah
Factor (HF) and Cl1, respectively), were measured during the process of rat
cardiac allograft rejection. Determination of which cytotoxic cytokine products
are present post-tranplantation and when during the time course of rejection,
may lead to more effective therapies aimed at promoting graft success.

Furthermore, the achievement of successful cardiac transplantation is, in
fact, critically dependent on immunosuppressive agents that can effectively
prolong graft survival and prevent allograft rejection. The current protocol of
administering potent immunosuppressive drugs to transplant recipients
dramatically increases the chances of graft survival, accompanied frequently,
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however, by toxic side effects. One approach to alleviating adverse side effects
associated with high dose immunosuppression employs the administration of a
combination of low dose immunosuppressive agents that may act additively or
synergistically to inhibit alloactivation. Studies in this dissertation were
designed to examine the use of a low dose cyclosporine A (CSA)/methothrexate
(MTX) combination therapy following cardiac transplantation. Specifically, the
ability of low dose CSA/MTX combination treatment to prolong cardiac allograft
survival was determined. Additionally, the expression of cytotoxic genes, TNFa,
LT, HF, and C11, in the transplanted cardiac grafts was measured in combination
CSA/MTX-treated recipients. Studies such as these may provide opportunities
to promote graft survival by using combination therapies which may minimize
adverse side effects.

Historical Background
The first half of the twentieth century was characterized by a debate
between proponents of pure cellular participation and proponents of the
antibody and complement system as agonists in graft rejection. In the early 1940s
the cellular nature of the alloimmune response was reported, and the allogeneic
rejection reaction was largely attributed to cellular immune responses (Gibson &
Medawar, 1943; Medawar et al., 1944). By the mid 1950s, the transplant rejection
response was characterized as the result of cell-mediated (Billingham et al., 1954)
and antigen-specific (Gorer, 1938) events. Despite the fact that the allograft
rejection response has been shown to be a result of antigen-specific cellular
mechanisms, the pathophysiological events which lead to the destruction of
foreign donor tissue have yet to be elucidated. There are a number of
mechanisms which have been proposed as effectors of graft rejection, including
2

cytotoxic alloantibodies (Carpenter et al., 1976), delayed-type hypersensitivity
(Loveland & McKenzie, 1982), cytotoxic T cells (Lowry et al., 1985a; Hall et al.,
1978), natural killer (NK) cells (Strom et al., 1977), and macrophages (MacPherson
& Christmas, 1984). It is not known, however, to what extent each of these

effectors may contribute to rejection of the transplanted graft. Therefore, it is
clear that a more detailed examination of discrete cellular mechanisms and
subpopulations involved in graft rejection needs to be performed.

Mechanisms of Allograft Rejection

Role of Genetics and the MHC
Although the immunological basis for transplant rejection has been well
established, the detailed cellular mechanisms responsible for the destruction of
donor tissue by the host's immune system are not yet fully understood. Early
studies have indicated that grafts which were transplanted between genetically
identical individuals or isografts were accepted, whereas grafts transplanted
between genetically non-identical individuals or allografts were rejected (Little &
Tyzzer, 1916). In fact, it has been demonstrated that successful transplantation
depends on the donor and recipient sharing a number of independently
segregating alleles, known as the histocompatibility genes (Gorer et al., 1948).
Genetic studies on the segregation of histocompatibility genes have shown a
large number of independently segregating loci in all vertebrate species.
However, there is one gene region or cluster, the major histocompatibility
complex (MHC), also referred to in humans as the human leukocyte antigen
complex (or HLA), which elicits stronger allogeneic reactions than the others
(Dausset et al., 1965; Hart & Fabre, 1981). The MHC maps to a single
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chromosome, located on the short arm of chromosome 6 in humans (Robinson
1989), and encodes four classes of genes, the first two of which provide the major
antigenic stimulus in allograft rejection. MHC class I products are constitutively
expressed in humans by most tissues and cells except erythrocytes. Class II
products are much more limited in distribution and are normally expressed on B
lymphocytes, dendritic cells, monocytes and macrophages, as well as most
endothelia, but may be induced on other cell types by gamma interferon (IFNy)
(Fuggle et al., 1986).

The MHC products, which are commonly referred to as the MHC
antigens, consist of heterodimeric cell surface molecules that are highly
polymorphic. MHC is essential for reactions involving the immune response
because they are responsible for antigen presentation and self-recognition
(Benacerraf, 1981). Although non-MHC antigens may contribute to graft
rejection (Witherspoon & Storb, 1989), the strongest rejection responses appear to
be directed against the products of the MHC, specifically class I and class II
antigens (Dausset et al., 1965; Hart & Fabre, 1981). In fact, the immune system is
commonly referred to as being "MHC-restricted" (Zinkernagel & Doherty, 1974).
Mature T cells express receptors (TCR) that recognize foreign antigens
which are generally in the form of short peptides bound to self MHC molecules
(Jorgenen et al., 1992) (Figure lA). In normal host defense mechanisms,
exogenous antigens are presented in the context of Class II, whereas
intracellularly derived antigens such as viral proteins are processed and
presented in association with MHC class I. The transplantation of MHCmismatched tissue presents an interesting variation in T cell recognition of
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antigen because the foreign antigens themselves are MHC molecules. Initiation
of allograft rejection is thought to involve recognition of donor allogeneic MHC
antigens expressed on the allograft and/ or on "passenger leukocytes" within the
graft, by receptors of CD4 +/T helper cells of the recipient. Activated CD4 + T
cells, along with antigen presenting cells, produce cytokines that support
lymphocyte proliferation and maturation of CDS+ cytotoxic T cells which are
specific for donor class I MHC. Infiltrating T cells may recognize processed
endogenous peptides in the context of self MHC (Figure lC), or processed
allogeneic MHC antigens presented in association with self-MHC (Figure 1D).
Additionally, direct recognition of epitopes on native alloantigen can also occur
(Figure lB). Support for these mechanisms of T cell recognition of alloantigen
exists, but is not discussed here (Reviewed in Krensky et al., 1990).

Cells Mediating Allograft Rejection
The host cells infiltrating into acutely rejecting tissues include T and B
lymphocytes, macrophages, and NK cells (Tilney 1975 and Mason 1986).
Progressive infiltration of allografted tissues by host mononuclear cells is
characteristic of the rejection process. Following transplantation, host
lymphocytes infiltrate perivascular areas and subsequently scatter throughout
the graft parenchyma. As inflammatory reactions proceed, macrophages become
increasingly prevalent, with disruption of peri-capillary tissues, progressive
interstitial inflammation, and eventual tissue necrosis. At the same time, both
mature and blastic lymphocytes increase within recipient lymphoid
compartments (Tilney 1991).
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A

B
TCR

TCR

D

C
TCR

Fig. 1. Possible mechanisms of T cell recognition of alloantigen. T cell receptors
(TCR) typically recognize foreign antigens in the form of short processed
peptides bound to self MHC (A). However, during transplantation of an
allograft, infiltrating T cells may recognize allogeneic MHC antigens as foreign
(B), TCR may recognize self-peptides in the context of allogeneic MHC located on
the allograft or passenger leukocytes (C), or processed allogeneic MHC peptides
may also be recognized by the TCR when presented in association with selfMHC (D).

T-Cell Activation and Proliferation
As mentioned earlier, the early T cell response to alloantigen is primarily
by the CD4+ /T helper cells that detect foreign MHC class II antigens on the
allografted tissue. It has also been shown, however, that much of the initial
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immunogenicity of the transplanted graft may be a response by the recipient T
cells against passenger leukocytes, which are dendritic leukocytes within the
graft that express high levels of MHC class II antigen (Larsen, et al., 1990). Once
recognition of foreign or allogeneic antigen occurs, transmembrane signals lead
to intracellular activation and subsequent expansion and differentiation of the
recipient's T lymphocytes. Early intracellular events in this process include the
phosphophatidylinositol and the tyrosine kinase pathways, which act as second
messengers during T cell activation.

In the phosphophatidylinositol pathway, activation of intracellular
phospholipase C cleaves phosphatidylinositol 4, 5-biphosphate (PIP2) into two
potent second messengers, inositol 1, 4, 15-triphosphate and diacyl glycerol,
which results in a 10-fold increase in intracellular calcium levels and activation of
protein kinase C, respectively (Krensky et al., 1990). Calcium-activated kinases,
in turn, modify DNA binding proteins, thereby affecting gene expression (in
particular interleukin-2 (IL-2)) and ultimately T cell activation and
differentiation. The tyrosine kinase pathway is directly activated by membrane
receptor recognition of foreign or allo-antigen. Tyrosine kinase phosphorylates
phospholipase C which in turn activates PIP2, again leading to T cell activation.

Activated CD4 + T cells, along with antigen presenting cells, produce
cytokines that support lymphocyte proliferation and the maturation of CDS+
cytotoxic T cells specific for donor class I MHC. The primary responsibility of T
cells in the acute destructive process relies on their ability to lyse donor target
cells without the need for antibody (Hayry & Defendi, 1970).
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Macrophage Response During Allograft Rejection
Following TCR-antigen recognition, host macrophages are thought to
provide the essential second signal, IL-1, which serves to trigger the proliferation
of CD4+ T cells (Halloran et al., 1989). IL-1 also possesses many other
proinflammatory effects, including promoting B cell growth and differentiation,
increasing the cytotoxicity of NK cells, potentiating platelet activating factor by
macrophages, and possessing chemotactic effects on macrophages (Halloran et

al., 1989). In addition to IL-1, activated macrophages also have the ability to
produce the cytokine, tumor necrosis factor alpha (TNFa). Like IL-1, TNFa
possesses many proinflammatory effects which may contribute to the allograft
rejection response. These effects include: potent induction of chemotactic factors
for polymorphonuclear leukocytes and monocytes (Baggiolini et al., 1989), which
may cause infiltration of these effector cells to the site of acute rejection,
augmentation of class I MHC antigen expression (Tracey et al., 1987), stimulation
of endothelium-derived platelet activating factor, which may promote ischemia
within the graft, and induction of macrophage activation.

In fact, the macrophage has been implicated as an effector cell in first-set
(acute) allograft rejection (MacPherson & Christmas, 1984), and their numbers
have been shown to dramatically increase during rejection (Leendert et al., 1992;
Payne et al., submitted). Specifically, macrophages have been described to be the
predominant infiltrating cell at the time of rejection and are present in intimate
relationship to myocardial cells (Christmas & MacPherson, 1982; Forbes &
Guttmann, 1983). Furthermore, macrophages have the ability to act both as
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antigen presenting cells that initiate an immune response and as cytotoxic
effector cells that contribute to graft destruction (Nathan et al., 1980).

Other Immune Cell Populations Found in Rejecting Grafts
In addition to T lymphocytes and macrophages, other cell populations
infiltrate rejecting grafts. B lymphocytes, when stimulated by alloantigen,
differentiate into antibody-producing plasma cells. B cells have been
demonstrated to appear late during the first-set acute allograft response and are
detected within graft infiltrates by the time rejection in complete (Payne et al.,
submitted). B cells from graft infiltrates have the ability to secrete both
nonspecific antibodies and those directed against donor cells (Garovoy et al.,
1982). However, despite their obvious activity, their actual role in acute cellmediated rejection remains unknown and is not well defined.

NK cells are a population of cytotoxic leukocytes that play a central role in
the host defense against some malignancies. Although they infiltrate organ
allografts rapidly, deletion experiments in graft recipients using specific anti-NK
cell antibodies show that they are not critical in the acute rejection process
(Heidecke et al., 1985). However, NK cells have been shown to mediate
resistance to allogeneic and semi-allogeneic bone marrow grafts. Therefore the
possibility exists that NK cells may effect rejection of allografts. In fact, it has
been suggested that NK cells present at the graft site may develop into
alloimmune cytotoxic T lymphocytes, or that NK cells may be functioning to
promote the allograft response; perhaps by their ability to secrete lymphokines,
such as IL-1 or IFNy, and/ or cytotoxic serine proteases (Hoffman et al., 1988).
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Other cell types, including neutrophils and eosinophils, are present within
the rejecting allografts, but their contribution, if any, to the rejection process is
poorly defined.

Effector Arms of Graft Destruction
After placement of an allograft, a leukocyte infiltrate accumulates at the
graft site. It is presumed that there are two principal means by which these
infiltrating cells promote allograft rejection: either directly, through cellmediated injury or lysis of the graft target cells (Figure 2A), or indirectly, through
local production of soluble mediators of the immune response (i.e., cytokines),
which in turn lead to graft target cell death (Figure 2B).

Fig. 2. Two examples in which infiltrating cells may mediate graft target cell
destruction. Foreign MHC class II antigens on graft stimulate host helper T cells
to help cytotoxic T cells to destroy graft target cells; cytotoxic T cells can also
recognize MHC class I foreign antigens, leading to direct cell lysis of graft target
cells (A). Helper T cells and macrophages, for example, can respond to foreign
graft cells by producing certain soluble mediators of the immune response, or
cytokines, which can either directly injure graft target cells themselves, or do so
by recruiting and activating nonspecific components of graft destruction (B).
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Direct Cell Lysis
As mentioned earlier, activated CD4+ cells, along with antigen presenting
cells, such as the macrophage, have the ability to produce certain cytokines that
aid in the maturation and subsequent activation of CDS+ specific cytotoxic T
cells. These activated cytotoxic T cells are then able to lyse foreign graft target
cells through direct cell contact. Direct graft cell lysis is thought to result from
the release of a preformed membrane-disrupting protein called "perforin," which
shares structural homology to the C5b-C9 "membrane attack complex" of the
complement cascade (Shinkai et al., 1988). The released perforin monomers bind
to the membrane of graft target cells and polymerize to form pores that
subsequently allow ion fluxes and entrance of cytolytic proteases, thus leading to
cell death (Reviewed in Berke, 1991).

Furthermore, although the importance of specific anti-graft antibodies in
acute rejection is uncertain, B lymphocytes are also known to be activated by T
cell products in the presence of antigen to produce high levels of anti-class I
antibodies. These antibodies are thought to be important in hyper acute
rejection, accelerated vascular rejection, and antibody-dependent-cell-mediated
cytotoxicity (Morris et al., 1990).
Production of Inflammatory Mediators
Promotion of allograft rejection by infiltrating cells may also occur
indirectly, through effects resulting from the local release of inflammatory
mediators which cause subsequent graft cell death. Production of these
mediators may either directly injure graft target cells themselves, or do so by
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recruiting and activating nonspecific components of graft destruction. Halloran

et al (1989) summarized the relevance some of these inflammatory mediators
have to the rejection process. These include: 1) the activation of macrophages as
well as inhibition of their migration from the graft (primarily by IFNy), leading to
increased macrophage release of cytokines (IL-1 and TNFa), eicosanoids, and
reactive oxygen intermediates; 2) the recruitment (by IL-l,IL-8, and other
chemokines) of polymorphonuclear leukocytes; 3) secondary effects of platelet
and coagulation activation which leads to graft ischemia; and, 4) the direct,
nonspecific cell necrosis capability of TNF, and perhaps IL-1 and IFNy, at
concentrations found within acutely rejecting grafts (Reviewed in Halloran et al.,
1989).

Taken together, both specific and nonspecific components of allograft
rejection leads, in the absence of immunosuppression, to an intense immune cell
infiltrate and subsequent graft cell destruction observed in acute rejection.

The focus of this dissertation is the investigation of the role of certain
soluble mediators of the immune response produced during rat cardiac allograft
rejection is investigated. A subset of these proteins which are known to be toxic
to cells, including the cytokines TNFa and LT, and the granzymes A and B (HF
and Cll, respectively), were evaluated for their role(s) in the host's response to
transplanted rat cardiac tissue. Insight into which of these cytotoxic proteins are
produced, and when during the course of allograft rejection, may provide
opportunities for both the detection of early markers of graft rejection and the
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design of improved immunosuppressive therapies which may be used to
prolong graft survival.

Cytokines and Granzymes in Allograft Rejection

Historical Background
As previously stated, the immune process in response to alloantigen is in
part due to the production by different cell types of soluble endogenous
biological mediators, among which are cytokines. Cytokines are soluble proteins
produced by a variety of hematopoietic cells that have the ability to regulate the
local development of alloreactivity. Cytokines can promote graft rejection by
increasing MHC class II antigen expression (Hall et al., 1984; Fuggle et al., 1987),
inducing adhesion molecule expression (Reviewed in Pober & Cotran, 1990),
providing growth and differentiation signals to effector cells, and in some cases,
directly damaging the graft parenchyma (Halloran et al., 1989).

Initial studies investigating the relevance of cytokines to allograft
rejection have taken advantage of the development of specific immunoassays
and bioassays that allow measurement of the cytokines of interest in biological
fluids. Generally, the strategy has been to measure specific cytokines in the
blood or urine of transplant recipients prior to, and following, graft
transplantation, and to attempt to correlate changes in cytokine levels with
clinical status. Identification of a given cytokine during rejection episodes
suggests but does not prove its participation in the rejection process.
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Several investigators have reported increased serum or plasma levels of
TNFa (Maury & Teppo, 1987; Hoffman et al., 1991), IL-1~ (Tilget al., 1990;
Hoffman et al., 1991), and IL-6 (Caillat-Zuckman et al., 1991) in patients at the
time of acute rejection episodes. Additionally, elevated levels of TNFa have also
been detected in the urine of rejecting human transplant recipients (McLaughlin
et al., 1991). In patients receiving renal allografts, increased IL-2 (McKenna et al.,

1988) and IL-2 receptor (Simpson et al., 1989) levels were observed in the
periphery during acute rejection episodes. However, IL-2 and IL-2 receptor,
along with TNFa, were also found to be significantly increased during bacterial
or viral infection (Maury & Teppo, 1987; McKenna et al., 1988; Simpson et al.,
1989; Imagawa et al., 1990a). Therefore, although changes in peripherallymeasured cytokines often accompany allograft rejection and may provide
information concerning the events occurring within the graft, the specificity of
the data recovered, especially regarding their role in the pathogenesis of the
acute rejection process, is very difficult to interpret.

In fact, systemic or circulating cytokine levels may not accurately reflect
events occurring in the local intragraft environment. Although elevated
circulating proinflammatory cytokines are found during acute rejection,
infections in general and viral infections in particular, may elicit the same pattern
of cytokine expression. In addition, it has previously been shown that cytokines
may circulate bound to other proteins, such as natural inhibitors (Larrick, 1989),
soluble receptors (Dinarello et al., 1993), preformed auto antibodies (Bendtzen et
al., 1990), and a2-macroglobulin Games, 1990), which inhibit their biological

activity but do not affect their immunoreactivity. Detection of an abnormally
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elevated cytokine in the systemic circulation does not necessarily prove that the
mediator is biologically active. Therefore, in situ measurement of these immune
mediators at the graft site is a far more accurate and reliable method of
identifying the cytokines elaborated during allograft rejection.

Cytokine Production Within Rejecting Allografts
During the last few years, the development of sensitive molecular
techniques that allow identification of cytokine mRNA in small amounts of tissue
or in limited numbers of cells has been paramount in characterizing the local
cytokine pathways that are elaborated during allograft rejection. For example, in
situ hybridization, as well as polymerase chain reaction (PCR) amplification have
recently been employed to address this issue. Recently, IL-6, TNFa, and IFNy
gene expression was examined by in situ hybridization techniques in human
renal allografts (Vandenbroeke et al., 1991; Noronha et al., 1992). It was found
that the majority of samples taken from rejecting kidneys contained elevated
levels of IL-6 gene transcripts, which were localized within glomerular cells,
endothelium, tubular epithelia, and the infiltrate; IFNy and TNFa mRNA,
however, were not found to be associated with rejection. These findings
implicate a role for IL-6 in the pathogenesis of human kidney allograft rejection.

Krams, et al. analyzed cytokine gene expression by PCR amplification in
both rejecting and rejected renal allografts (Krams et al., 1992). IL-1~, IL-6, and
TNFa gene transcripts were prominent in rejected allografts, (supporting the
concept that end-stage transplants are sites of ongoing inflammation); IL-6 and
TNFa mRNA transcripts were detected less frequently in rejecting allografts than
rejected allografts, while IL-1~ mRNA was not evident. Conversely, gene
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transcripts for the immune mediators IL-2, IL-4, and IL-5 were more prevalent in
rejecting allografts than in end-stage transplants, suggesting that different
immunologic processes may predominate depending on the progression of
rejection. Wu et al (1992), also utilized the methodology of PCR amplification to
detect cytokine mRNA transcripts in biopsies obtained from heterotopic
abdominal cardiac allografts. IFNy mRNA transcripts were detected in all
transplants two days after surgery, before evidence of rejection was
demonstrable by histopathologic analysis. IL-1~, IL-2, and IL-6 gene transcripts
were detected when minimal rejection was noted, and IL-la, IL-1~, IL-2, IL-6, IL8, TNF~ (LT), and IFNymRNA transcripts were detectable in end-stage
transplants (Wu et al., 1992).

Recently, Lipman, et al (1992) investigated cytokine gene expression for IL1~, IL-2, IL-6, TNFa, and the cytotoxic T cell-specific serine protease, Cl1, in
biopsies obtained from human renal allografts. The core biopsies were classified
into three different categories based on histology: no evidence of rejection, acute
cellular rejection, and equivocal rejection. IL-1~, IL-2, IL-6, and TNFa mRNA
transcripts were detected in all biopsy classifications, with no difference in the
frequency of gene expression of any of the aforementioned cytokines in relation
to histology. However, C11 gene expression notably correlated with rejection.
These results support a primary role for cytotoxic T lymphocytes in the cellular
mechanisms of renal allograft rejection.

Although specific mechanisms have not yet been elucidated, there is
enough data to indicate that cytokines play an important role in the pathogenesis
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of allograft rejection, and may prove to be a useful target to disrupt the rejection
process. In the present dissertation, employment of the previously mentioned
methodology, that is, intragraft measurement of specific cytokines in
transplanted rat cardiac tissues, is utilized to detect cytotoxic cytokine levels
during the evolution of graft rejection. Specifically, TNFa and LT, as well as two
cytotoxic T cell-specific serine proteases of the granzyme family, HF and Cll,
will be examined for their putative roles in the rejection process of
heterotopically transplanted rat cardiac allografts.

Tumor Necrosis Factors-a and -6
TNFa and -~ (LT) are two closely related cytokines that are endogenous

mediators of immunological and inflammatory events. TNFa is a small peptide
cytokine with a molecular weight of 17 kD which is produced primarily by
activated macrophages (Beutler et al., 1985a), but recently has also been shown to
be synthesized by activated peripheral T lymphocytes (Steffen et al., 1988). LT is
a glycoprotein with a molecular mass of 25 kD originally identified as a cytolytic
factor produced by cultured T lymphocytes in response to challenge with an
antigen to which the cells had previously been exposed in vivo (Ruddle &
Waksman, 1967), or in response to nonspecific mitogenic stimuli, (i.e., lectins)
(Granger & Williams, 1968). TNFa and LT share 36% and 51 % structural
homology in overall nucleotide and amino acid sequences, respectively (Pennica

et al., 1984), and also appear to have common receptor-binding domains
(Aggarwal et al., 1985a).

Although TNFa and LT are distinct biochemically, they exert similar
immunological effects in vitro (Ruddle, 1985; Beutler & Cerami, 1986). One of
17

the many biological activities of TNFa and LT includes activation of
macrophages and enhancement of their cytotoxic potential in vitro (Aggarwal et

al., 1985b). In addition to their cytotoxic effects, TNFa and LT have been shown
to activate T lymphocytes, B lymphocytes, and NK cells (Yokota et al., 1988;
Kehrl et al., 1987), and to elicit an increase in IL-1 and IL-6 synthesis and IL-2
receptor expression by cultured macrophages and T cells (Beutler et al., 1985b).

The specific roles of TNFa and LT in allograft rejection, however, are less
well defined. As previously mentioned, TNFa has many proinflammatory
actions which have been implicated to contribute to the allograft rejection
response. These effects include: potent induction of chemotactic factors for
polymorphonuclear leukocytes and monocytes (Baggiolini et al., 1989), which
may cause infiltration of these effector cells to the graft site, augmentation of
class I MHC antigen expression (Tracey et al., 1987)), stimulation of endotheliumderived platelet activating factor, promoting ischemia within the graft, and
induction of macrophage activation.

Macrophages, in fact, have been shown to be major components of the
cellular infiltrate in transplanted organs undergoing rejection (Strom et al., 1977),
and have been implicated as an effector cell in first-set (acute) allograft rejection
(MacPherson & Christmas, 1984). Macrophage numbers have been shown to
dramatically increase during rejection (Leendert et al., 1992), and have been
described to be the predominant infiltrating cell at the time of rejection
(Christmas & MacPherson, 1982; Forbes & Guttmann, 1983). Furthermore,
macrophages can act as antigen presenting cells that have the ability to induce
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immune responses, and as effector cells able to cytotoxically damage and cause
eventual necrosis of graft target cells (Nathan et al., 1980). For these reasons, the
present dissertation investigates TNFa, primarily an activated macrophage cell
marker, for its possible role during the process of acute allograft rejection of rat
cardiac transplants. Additionally, because TNFa and LT are known to exert
similar immunological effects (Ruddle, 1985; Beutler & Cerami, 1986), and in
fact, bind to common receptor domains (Aggarwal et al., 1985a), the studies
contained within this dissertation also examined the putative role LT may
contribute to acute rejection of rat cardiac allografts.

It has previously been reported that a marked elevation of serum TNFa
levels exists during rejection episodes in human renal allograft recipients (Maury
& Teppo, 1987). In addition, serum TNFa levels in cardiac allograft recipients

have been shown to correlate with severity of rejection based on histological
assessment of endomyocardial biopsies Gordan et al., 1993). TNFa activity has
also been demonstrated in homogenates from rejecting rat cardiac allografts
(Lowry & Blais, 1988), and localized to mononuclear cell infiltrates in increased
amounts during rejection (Hancock et al., 1991). Cytotoxic activity, attributed to
LT, has been reported in both rejecting human (Moy & Rosenau, 1981) and rat
(Lowry et al., 1985b) renal allografts. Recent studies have reported successful use
of anti-TNFa and LT antibodies in prolonging the survival of transplanted grafts
(Imagawa et al., 1990b; Scheringa et al., 1991; Teramoto et al., 1991), as well as
reducing cellular infiltrates and edema (Saito et al., 1993) in rat models of
rejection, indicating the contribution of TNF in mediating acute rejection. These

19

data strongly suggest a role for TNFa and/ or LT in the pathogenesis of allograft
rejection.

Granzymes A and B (HF and Cll)
Granzymes are a family of highly homologous serine proteases present in
secretory granules of cytolytic T lymphocyte cells. Seven serine proteases have
been identified (granzymes A through G) (Reviewed in Masson & Tschopp;
Jenne & Tschopp, 1988) from cytolytic granules of murine cytotoxic T
lymphocytes and NK cells, and four serine proteases have been identified from
human cytolytic lymphocytes (granzymes A, B, 3, and H) (Reviewed in Griffiths
& Mueller, 1991a). Besides granzymes, perforin and proteoglycan molecules of

the chondroitin sulfate A type, are the other two major constituents of these
cytolytic granules (Krahenbuhl & Tschopp, 1991). Granzymes have been
implicated in cell-mediated lysis by the observation that lysis by cloned T cells
and isolated granules is inhibited by treatment with serine protease inhibitors
(Chang & Eisen, 1980; Acha-Orbea et al., 1983). However, the physiologic role of
granzymes is unknown. There is considerable evidence that the cytolytic
granular components of cytotoxic T cells are released upon effector-target cell
binding (Bykovaskaja et al., 1978). In fact, granzymes and proteoglycan
molecules have been detected in the culture medium of cytotoxic T lymphocytetarget cell conjugates (Pasternack et al., 1986; Takayama et al., 1987). Granzymes
by themselves, however, do not have cytolytic activity (Masson & Tschopp, 1985;
Podack et al., 1985). Yet in combination with purified perforin, granzymes can
affect the release of target cell DNA, an event which occurs during cell-mediated
lysis (Hayes et al., 1989).
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An attractive model for "lethal hit delivery" has been proposed describing
the events leading to target cell lysis. This granule-exocytosis model suggests
that, upon appropriate effector-target cell conjugation, the effector cells deliver
dense cytoplasmic granules and their contents into the intercellular space at the
site of contact between the target and effector cell (Sitkovsky, 1988). This process
of degranulation releases perforin, which, upon polymerization and in the
presence of Ca 2+, induces transmembrane, ring-like pores in the target cell
membrane. The formation of pores in the target cell membrane subsequently
allows ion fluxes and access to the released granular contents, including
granzymes, which leads to target cell apoptosis and eventual cell death (Berke,
1991) (summarized in Figure 3).

c::::::- perforin

"jl proteoglycan
Q granzymes
graft
target cell

T cytotoxidNK
cell

Fig. 3. Proposed granule-exocytosis model for "lethal hit delivery," leading to
target cell lysis.
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As stated earlier, cytotoxic T lymphocytes are believed to be important
effector cells in the destruction of transplanted tissue during allograft rejection
(Loveland & McKenzie, 1982; Lowry et al., 1985b). After recognition of
alloantigens on the surface of MHC-nonidentical target cells, cytotoxic effector
cells bind to them and induce target cell lysis (Hall et al., 1978). Although various
steps in this process have been analyzed in considerable detail, most studies have
not provided insight into the mechanism(s) by which the cytolytic effector cell
administers the "lethal hit" to the target cell. Recently, the genes encoding the
serine esterases HF and Cll (Granzymes A and B, respectively), which have been
demonstrated to be selectively expressed in cytotoxic cells including cytotoxic T
lymphocytes and NK cells, have been cloned (Gershenfield & Weissman, 1986;
Lobe et al., 1986). The kinetics of HF and Cll gene expression closely parallel the
cytolytic responses in vitro, in that the observed kinetics of serine esterase release
and of the delivery of the lethal hit are consistent with the hypothesis that both
events occur simultaneously (Gershenfield & Weissman, 1986; Lobe et al., 1986).
Therefore, a strong correlation exists between granzyme gene expression and
cytotoxic potential. For these reasons, this dissertation investigated the
expression of both HF and Cl 1 serine proteases for their putative role in the
process of acute allograft rejection of rat cardiac transplants.

One of the first studies demonstrating the importance of granzymeexpressing lymphocytes in vivo, involves the detection of transcripts encoding
serine proteases in situ, during murine cardiac allograft rejection (Mueller et al.,
1988). In this study, the time course of serine protease expression closely
paralleled the rejection process. Recently, both granzymes A and B have been
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described as putative markers for rejection in patients following cardiac
transplantation (Griffiths et al., 1991b; Clement et al., 1991), as well as in
experimental animal models of cardiac (Mueller et al., 1991) and renal (Lipman et
al., 1992) allograft rejection. Therefore, these data would suggest that cytotoxic

cell-specific serine proteases, such as HF and Cl 1, may play a role in the
pathogenesis of rat cardiac allograft rejection.
Immunosuppression to Prevent Allograft Rejection

Historical Background
Therapeutic attempts to prevent allograft rejection have gradually evolved
from nonspecific suppression of immune responsiveness to the modulation of
specific components of rejection. In the late 1950s, a single incidence of long-term
success was achieved with total body irradiation for a human renal allograft
transplanted into a fraternal twin recipient (Murray et al., 1960). In the early 60s,
Caine, et al (1962) demonstrated the usefulness of mercaptopurine, a purine
analog antimetabolite that nonspecifically inhibits gene replication therefore
affecting T cell proliferation and antibody synthesis. In this study,
mercaptopurine was found to be successful in prolonging canine renal allografts,
and soon after, its parent compound, azathioprine, became commonly used in
clinical settings. Subsequently, the beneficial synergistic effect of steroids with
azathioprine was realized, and the introduction in the 1960s of antilymphocyte
serum in conjunction to this combination therapy, especially for the reversal of
acute rejection, came into use (Reviewed in Murray et al., 1981). However,
adverse side effects, including leukopenia, thrombocytopenia, and allergic
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reactions to heterologous serum as well as anti-lymphocyte serum antibody
production limited its long-term use.

The decade of the 1980s was highlighted by the introduction and
application of cyclosporine A (CSA) in the field of organ transplantation. CSA
was first used clinically in 1978 (Caine et al., 1978), and because it was
demonstrated to be a potent immunosuppressive agent acting at the level of the
T lymphocyte, CSA was subsequently used therapeutically following organ
transplantation.
Cyclosporine A
CSA is a cyclic endecapeptide derived from the soil fungus, Tolypocladium

infiatum, and as stated earlier, has been demonstrated to be a potent
immunosuppressive agent and inhibitor of helper T cell function (Borel et al.,
1976; Orosz et al., 1983). The profound, reversible suppression of cell-mediated
immunity caused by CSA was first described by Borel et al (1976), and since those
landmark studies, it has been the focus of numerous investigations to examine its
exact mechanism(s) of action. CSA has been shown to consistently inhibit IL-2
gene transcription (Kronke et al., 1984; Elliot et al., 1984), and therefore, the direct
effects of CSA upon CD4 + T helper lymphocytes have become the central focus of
most efforts attempting to elucidate CSA's immunosuppressive action, since one
functional characteristic of the CD4+ T helper lymphocyte population is the
biosynthesis and release of an array of cytokines, including IL-2.

IL-2 is a T helper cell product that functions as a second signal in the
presence of appropriate antigen to promote the differentiation and clonal
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expansion of mature T lymphocytes and appears to be an important mediator in
allograft rejection, since a positive correlation between IL-2 levels and rejection
episodes has been described (Yoshimura & Kahan, 1985; Vie et al., 1985;
McKenna et al., 1988). Anti-IL-2 receptor antibodies have also been shown to
prevent allograft rejection in experimental models, thus supporting the central
role IL-2 plays in the rejection process (Kirkman et al., 1985). Although CSA's
action on IL-2 gene expression in T cells is currently taken as the prototype for all
its immunosuppressive effects, CSA also has effects on many other cell types,
and on their cytokine production. In mast cells, CSA has been demonstrated to
block degranulation as well as transcriptional activation of several cytokine
genes, including IL-3 and IL-5 (Cirillo et al., 1990; Hultsch et al., 1991). In
stimulated THP-1 cells, a leukemic monocyte cell line, CSA has been shown to
inhibit the in vitro production of both IL-la and IL-1~ (Reisman et al., 1991). CSA
has also been reported to inhibit in vitro-stimulated cytokine production by
peripheral blood mononuclear cells; these cytokines include IL-2, IFNy, IL-4, IL-5,
and TNFa (Andersson et al., 1992).

As stated earlier, most studies investigating the actions of CSA have
concentrated on T cells as the targets for CSA immunosuppression. However,
recent attention has also focused on the role of the macrophage. Benson et al
(1989) demonstrated that decreased IL-2 production observed with CSA
treatment is actually caused by inhibition of macrophage antigen presentation.
Additionally, in vitro studies have shown that CSA inhibits production of TNF
(Espevik et al., 1987) without depressing mRNA or intracellular levels of TNF
(Remick et al., 1989). CSA has also been shown to block the extracellular
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production of TNF in response to lipopolysaccharide (LPS) challenge, both in

vitro and in vivo, without decreasing TNF mRNA (Nguygen et al., 1990).
Therefore, although CSA is generally accepted to act as an immunosuppressive
agent through potent inhibition of IL-2 production by T cells, CSA may also exert
its immunosuppressive actions through inhibition of additional cytokines
produced by different leukocyte populations.

While CSA effects upon cytokine biosynthesis and release have been
reproducibly demonstrated, the exact mechanism of CSA action remains to be
characterized. CSA is thought to enter target cells through passive transport by
diffusing through the plasma membrane lipid bilayer (LeGrue & Munn, 1986a),
concentrating on the inner membrane surface, and presumably gaining
intracellular access from that point (Rossaro et al., 1988). Investigation has
revealed that CSA binds to a number of intracellular proteins in extremely small
quantities with two notable exceptions. Calmodulin, a calcium binding protein
which undergoes a conformational change upon receptor-ligand interaction,
binds to CSA; however, the interaction is of relatively low affinity and has not
been linked to the biologic effects mediated by CSA (Hess et al., 1988; LeGrue et
al., 1986b). At high concentrations, CSA does exert some effects upon
calmodulin, but the collective data have argued against the interaction
representing a primary component of CSA's mechanism of action (Drugge &
Handschumacher, 1988).

Recently, the binding of CSA to an intracellular protein, cyclophilin, has
been reported (Handschumacher et al., 1984). Subsequent protein purification
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and sequence determination has revealed cyclophilin to represent a novel
molecule 17 kD in size and characterized by its ability to bend or fold proteins at
praline groups, from the "cis" to the "trans" position, and therefore described as a
peptidyl-prolyl cis-trans isomerase (Harding et al., 1986; Takahashi et al., 1989;
Fischer et al., 1989). CSA is thought to inhibit the rotomase enzyme activity of
cyclophilin. It has been postulated that CSA's immunosuppressive effect is due
to the inhibition of cyclophilin's isomerase activity, needed for signal
transduction (Lorber et al., 1990).

More recent evidence has shown that CSA specifically inhibits the DNA
binding activities of several nuclear factors important in transcriptional
activation of the genes for IL-2 and several other cytokines (Emmel et al., 1989;
Mattila et al., 1990). Specifically, the transcription factors NF-AT, AP-3, NF-AL,
and NF-KB, were found to be affected by CSA; each of these transcription factors
have a common distinguishing feature in that all require Ca 2+ mobilization for
activation. Therefore, the aforementioned observations have led to a working
hypothesis proposed by Schreiber et al (1992) by which CSA blocks IL-2 gene
activation, and possibly other cytokines, in T cells and other immune cell
populations (summarized in Figure 4).

In addition to its immunosuppressive capabilities, CSA has also been
shown to mediate a number of physiologic changes; the clinical manifestations of
these effects often resulting in toxic side effects. Therefore, although CSA has
been used with considerable success clinically to prolong organ graft survival,
significant adverse side effects, such as nephrotoxicity (Myers et al./, 1984),
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Fig. 4. Proposed model of CSA inhibition of cytokine (IL-2) gene activation.
Binding of antigen to TCR leads to intracellular Ca 2+ release. Calcium activates
the phosphatase, calcineurin which, in the absence of CSA, dephosphorylates
NF-ATc (cytosolic subunit) thus facilitating its translocation into the nucleus.
NF-ATc can then combine with NF-ATn (nuclear cofactor) to form an activated
transcription factor with the ability to activate RNA polymerase, thereby
regulating gene transcription. This process is blocked when CSA binds to its
receptor protein, cyclophilin. The CSA-cyclophilin complex can inhibit
calcineurin, which blocks nuclear translocation of NF-ATc, therefore inhibiting
cytokine gene activation.
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hepatotoxicity (Vine et al., 1988), hypertension (Munoz et al., 1988), as well as
neurological toxicities (deGroen et al., 1987) have been reported with its use.
Consequently, a need remains for implementing specific therapies directed at
achieving transplant success with a minimum of undesirable side effects.

As newer agents with immunosuppressive capabilities appear on the
horizon, the possibility of utilizing combination treatments has offered hope for
improved therapeutic management of organ transplantation. For example, the
introduction of both FK506 (Tanaka et al., 1987), an antibiotic tacrolimus isolated
from the soil fungus Streptomyces tsukubaenis, and rapamycin (Seghal et al., 1975),
another macrolide similar in structure to tacrolimus, have demonstrated potent
immunosuppressive activity (Beck & Akiyama, 1989; Morris et al., 1990).
Rapamycin, in particular, has been shown to exhibit marked synergy when
combined with CSA in inhibiting various parameters of in vitro immunological
performance by human peripheral blood lymphocytes (Kahan et al., 1991).
Monoclonal antibodies, such as OKT3, a murine monoclonal antibody against the
CD3 complex, have also shown promising results in the clinical management of
organ transplantation (Millis et al., 1989). Although these immunosuppressive
agents have demonstrated initial clinical success, their mechanisms of action as
well as their use in organ transplantation therapy will not be discussed in detail
within the present dissertation, but are reviewed elsewhere (Metcalf & Richards,
1990; Schreiber & Crabtree, 1992). It may be said, however, that despite their
promising immunosuppressive effects, FK506, rapamycin, and OKT3, similar to
CSA, all have certain adverse side effects associated with their use at therapeutic
doses. One possible approach to forego high dose toxicities is the utilization of
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combination treatments, administered at lower therapeutic doses, to achieve
increased survival time of organ transplants while minimizing adverse side
effects.
Methotrexate
One agent which may provide promising results for combination therapy
is methotrexate (MTX). MTX is classified pharmacologically as an antimetabolite
because of its antagonistic effect on folic acid metabolism and function (Mitchell

et al., 1969). MTX has been shown to bind dihydrofolate reductase which results
in the inhibition of DNA synthesis; this antiproliferative action has made MTX a
useful drug for cancer chemotherapy 0olivet et al., 1983). Compared to CSA,
little is known about the immunosuppressive actions of MTX. However, the
importance of MTX as an immunosuppressive agent was first considered when
anti-inflammatory effects were noticed with its utilization in the treatment of
rheumatoid arthritis, wherein MTX demonstrated both long term and short term
efficacy (Weinblatt et al., 1985; Perhala & Wilke, 1991). The mechanism(s),
however, by which MTX suppresses disease activity in inflammatory rheumatoid
arthritis is still poorly understood and adverse side effects, such as severe
leukopenia and gastrointestinal upset, have been associated with its use
(Weinblatt et al., 1985).

It has been postulated that MTX may exert its immunosuppressive action
by deactivation of macrophages. This would result in decreased IL-1 production
(Hu et al., 1988), as well as inhibition of macrophage migration, resulting in the
decreased accumulation of inflammatory cells and/ or immune mediators
0ohnson et al., 1988). Despite these findings, the administration of MTX has also
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been shown to restore both T cell function (Kourounakis & Kapusta, 1976) and
IL-2 production (Combe et al., 1985) in rheumatoid arthritis, thereby
counteracting the immunosuppressive effects demonstrated by Hu et al (1988).

MIX, however, has recently shown favorable results in treating
persistent mild (Olsen et al., 1990), as well as recurrent moderate to severe cardiac
allograft rejection (Costanzo-Nordin et al., 1988). Success has also been
demonstrated using CSA at doses of 10-15 mg/kg/ day combined with either
high or low dose MIX in the prevention of graft-versus-host disease after bone
marrow transplantation in experimental animal models (Deeg et al., 1982; Deeg

et al., 1984), as well as in human clinical studies (Storb et al., 1986; Truog &
Wozniak, 1990).

Taken together, immune processes in response to alloantigen is the
result of both direct cell-mediated events and the production of, by different cell
types, soluble biological mediators, including cytokines and granzymes. In the
absence of immunosuppression, these specific and non-specific components of
allograft rejection lead to intense immune cell infiltration and subsequent graft
cell destruction. Previous observations strongly suggest that administration of
CSA/MIX combination therapy may serve as a possible alternative treatment in
promoting allograft survival. Figure 5 summarizes the postulated mechanisms
of CSA/MIX immunosuppression on effector cells and cytokine/granzyme
production during allograft rejection. For these reasons, the focus of the present
dissertation is to examine the effects of a low dose CSA/MIX combination
therapy in prolonging rat cardiac allografts. Specifically, low dose CSA/MIX
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combination therapy will be evaluated for its ability to prolong rat cardiac
allograft survival time, as well as for its effect on cytotoxic cytokine expression,
including TNFa, LT, and granzymes A and B (HF and Cl1).
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Fig. 5. Possible mechanisms of CSA/MTX immunosuppression on effector cells
and cytokine/ granzyme production during allograft rejection.
Therefore, the major objectives of this dissertation project are: 1) to
quantitate the expression of the aforementioned cytotoxic cytokine gene products
during the evolution of graft rejection, and 2) to evaluate and compare the
efficacy of a low dose CSA/MTX combination therapy for its ability to prolong
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survival of rat cardiac allografts. These objectives will be fulfilled by
accomplishing the following specific aims: the expression of the genes encoding
the cytotoxic cytokines, TNFa and LT (Chapter II) and the serine proteases HF
and C11 (granzymes A and B, respectively) (Chapter IV), are quantitated during
rat cardiac allograft rejection. In Chapter III, the aims are: 1) to evaluate the
efficacy of a low dose CSA (1.0 mg/kg/day)/MTX (450 µg/kg/wk) combination
therapy in prolonging rat cardiac allograft survival, and 2) to determine the
effects of low dose CSA/MTX on IL-2 gene expression in rat cardiac allografts.
Finally, in Chapter IV, the effects of low dose CSA/MTX on the expression of the
cytotoxic cytokines, TNFa, LT, as well as the serine proteases HF and C11, are
determined in rat cardiac allografts during rejection.

Insight into which of the cytotoxic mediators are synthesized, and when
post-tx, may provide opportunities for early detection of molecular "markers"
that signal impending rejection. Assessment of the cytokine profile during
allograft rejection may also aid in the development of more specifically targeted
immunosuppressive therapies designed to prolong graft survival. Therefore, the
overall goal of these studies is to expand our knowledge of the
immunopathological mechanisms involved in graft rejection and to evaluate
more effective strategies aimed at prolonging graft survival while minimizing
adverse side effects often associated with the use of immunosuppressive agents.

33

CHAPTER2
INDUCTION OF TNFa AND TNF~ GENE EXPRESSION IN RAT CARDIAC
TRANSPLANTS DURING ALLOGRAFT REJECTION

Abstract

The expression of the cytotoxic cytokines, TNFa and LT, was assessed in
rat cardiac transplants during rejection. Newborn rat cardiac grafts placed in
adult rat ear pinnae were retrieved on days 1 through 10 post-transplantation
(post-tx); the average time to rejection, assessed by the absence of detectable
electrocardiographic (ECG) activity, was determined to be 7 days. Total cellular
RNA and tissue homogenates were prepared from cardiac transplants in order
that relative levels of TNFa and LT mRNA and TNF protein could be
determined. A biphasic pattern of TNFa gene expression was consistently seen
in cardiac allografts. TNFa mRNA transcripts were detected as early as day 2
post-tx, with peak levels appearing on day 3 post-tx. Although transcript levels
decreased by day 4, a significant increase appeared again on day 6 post-tx,
coincident with the onset of rejection. Similar to TNFa gene expression, LT
transcripts demonstrated a biphasic pattern of induction. LT mRNA transcripts
also reached peak levels on day 3 post-tx, with a second increase in transcript
levels coincident with rejection. TNF protein levels in allografts displayed a
biphasic pattern, similar to that shown by the cytokine mRNAs. Peak levels of
TNF protein were detected on day 3 post-tx, with a second increase again
coinciding with rejection. In contrast to TNF expression found in allografts,
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TNFa and LT mRNA transcripts were not detected in isografts on days 1 through
10 post-tx. TNF protein levels in cardiac isografts were consistently at or below
the standard limits of detection, and on days 3 through 7 post-tx were
significantly reduced (p ~ 0.001) when compared to time-matched allografts.
Increased expression of the cytotoxic cytokines, TNFa and LT, therefore, appears
to be allograft-specific and is an early event during rat cardiac allograft rejection.
In conclusion, induction of TNF gene expression may be an important early
indicator of transplant rejection.
Introduction

Although the immunological basis for transplant rejection has been well
established, the cellular mechanisms responsible for allograft rejection have not
yet been fully elucidated. After transplantation of a tissue allograft, a cellular
infiltrate consisting of leukocytes of several phenotypes appears within the graft
(Hanto et al., 1982). Infiltration of both helper and cytotoxic T lymphocytes
precedes the destruction of the allograft by several days, and it is believed that
these cells play a major role in the process of allograft rejection (Loveland &
McKenzie, 1982; Lowry et al., 1983). Macrophages and NK cells have also been
found to be major components of the cellular infiltrate in organ allografts
undergoing acute rejection (Strom et al., 1977; MacPherson & Christmas, 1984;
Nemlander et al., 1983). These cells proliferate and release a range of soluble
mediators of the immune response (i.e., cytokines) - which, among many other
effects, have been shown to damage blood vessels within the graft (Dvorak et al.,
1980), cause an increase in graft infiltration by leukocytes (Cox et al., 1984), and
stimulate the differentiation of graft-specific T cells at the graft site (Heidecke et
al., 1984). These events precipitate allograft damage and eventual necrosis of the

35

transplanted tissue. There are two principal mechanisms by which cell-mediated
injury may occur: through direct lysis of the graft target cells, or indirectly,
through local production of cytokines which, in turn, contribute to allograft
destruction.

TNFa and LT are two closely related cytokines that are endogenous
mediators of immunological and inflammatory events. TNFa is a small peptide
cytokine with a molecular weight of 17 kD which is produced primarily by
activated macrophages (Beutler et al., 1985a), but recently has also been shown to
be synthesized by activated peripheral T lymphocytes (Steffen et al., 1988). LT is
a glycoprotein with a molecular mass of 25 kD originally identified as a cytolytic
factor produced by cultured T lymphocytes in response to challenge with an
antigen to which the cells had previously been exposed in vivo , or in response to
nonspecific mitogenic stimuli, (i.e., lectins) (Ruddle & Waksman, 1967; Granger
& Williams, 1968). TNFa and LT share 36% and 51 % structural homology in

overall nucleotide and amino acid sequences, respectively (Pennica et al., 1984),
and also appear to have common receptor-binding domains (Aggarwal et al.,
1985a).

Although TNFa and LT are distinct biochemically, they exert similar
immunological effects in vitro (Beutler & Cerami, 1986; Beutler, 1990). One of
the many biological activities of TNFa and LT includes activation of
macrophages and enhancement of their cytotoxic potential in vitro (Aggarwal et

al., 1985b). In addition to their cytotoxic effects, TNFa and LT have been shown
to activate T lymphocytes, B lymphocytes, and NK cells (Yokota et al., 1988;
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Kehrl et al., 1987), and to elicit an increase in IL-1 and IL-6 synthesis and IL-2
receptor expression by cultured macrophages and T cells (Beutler et al., 1985b).

The specific roles of TNFa and LT in allograft rejection, however, are less
well defined. It has been reported that a marked elevation of serum TNFa levels
exists during rejection episodes in human renal allograft recipients (Maury
&Teppo, 1987). Similarly, serum TNFa levels have been found to be significantly
elevated in patients experiencing acute rejection following orthotopic liver
transplantation (lmagawa et al., 1990a). TNFa activity has also been
demonstrated in homogenates from rejecting rat cardiac allografts (Lowry &
Blais, 1988) and localized to mononuclear cell infiltrates in increased amounts
during rejection (Hancock et al., 1991). Cytotoxic activity, attributed to LT, has
been reported in both rejecting human (Moy & Rosenau, 1981) and rat (Lowry et
al., 1985b) renal allografts. Recent studies have reported successful use of anti-

TNFa and LT antibodies in prolonging the survival of transplanted grafts in
experimental animals, indicating the contribution of TNF in mediating acute
rejection (Imagawa et al., 1990b; Scheringa et al., 1991; Teramoto et al., 1991).
These data strongly suggest a role for TNFa and/or LT in the pathogenesis of
allograft rejection.

The purpose of this study was to quantitate the expression of the genes
encoding these two cytokines during rat cardiac allograft rejection. Insight into
which of these two cytotoxic proteins are synthesized, and when post-tx, may
provide opportunities for early detection of cytokine "markers" that signal
impending rejection. Assessment of the cytokine profile during allograft
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rejection may also aid in the development of more specifically targeted
immunosuppressive therapies designed to prolong graft survival.
Materials and Methods

Animals
Pregnant Brown Norway (BN) (RTln) and 6-8-week-old male Lewis
(RTll) rats were purchased from Harlan Sprague Dawley (Indianapolis, IN).
Dark Agouti (DA) (RTla) rats were obtained from an inbred rat colony
maintained at Loyola University Medical Center. All animals received water and
food ad libitum, and were housed in accordance with institutional animal care
and use guidelines. Two isograft groups were used in these studies: adult male
Lewis or DA rats served as recipients of donor cardiac tissues obtained from 1-3
day-old Lewis or DA rats, respectively. The two allograft groups consisted of
adult male Lewis rats serving as recipients of either 1-3 day-old BN or DA rat
cardiac transplants. The donor ages used have been previously reported to result
in optimum isograft viability (Fulmer et al., 1963) and were of appropriate size so
that whole heart grafts might be accommodated by the recipient's ear.
Cardiac Transplantation
The procedure utilized was a modification of the heterotopic method of
cardiac transplantation into the mouse ear as described by Fulmer et al (1963)
(Figure 6). Cardiac graft recipients were anesthetized with ketamine/xylazine
(20:1) (Fort Dodge Laboratories, Fort Dodge, IA and Rugby Laboratories, Inc.,
Rockville Centre, NY) at 105 mg/kg body weight i.p. prior to surgery. The
dorsal surface of the recipient's ear pinna was nicked at the proximal end with a
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sterile scalpel, and a subcutaneous pouch was prepared using blunt forceps.
Whole newborn hearts were harvested promptly at the time of donor sacrifice
and gently inserted into the ear pouches of the recipients. In order to prevent
graft loss and promote revascularization, skin flaps surrounding the graft site
were apposed by applying gentle pressure with forceps. Each recipient was
grafted bilaterally, one whole heart per recipient ear, with two isografts or two
allografts per animal. Cardiac graft recipients were anesthetized and monitored
from day 1 to day 10 post-tx by visual inspection for pulsatile activity and by
electrocardiography using pin electrodes placed on either side of the graft with
leads connected to a polygraph recorder ( Grass Instruments Model 79D, Quincy,
MA) (Figure 7). Grafts were removed on days 1 through 10 post-tx and
processed as described below for RNA blot analysis or protein assays.

NEWBORN
HEART DONOR

3.

(

CHECK
PULSATILE &ECG

J

ACTIVITY
DAILY

2.

4.

GRAFf RECIPIENT

Fig. 6. Schematic diagram of the heterotopic heart graft technique used in the
present studies. The dorsal surface of the recipient's ear pinna is nicked at the
proximal end (1). A subcutaneous pouch is prepared to accommodate grafts (2).
Whole newborn donor hearts are inserted into ear pouches (3). Cardiac grafts are
monitored daily (4).
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PHYSIOGRAPH RECORDER

®

©

Fig. 7. Illustration of physiograph recordings. Input from graft leads to
determine graft ECG activity (a). Input from intrinsic heart leads to determine
intrinsic heart's ECG activity (b ).

Cell and Tissue Culture
All cells were cultured in RPMI-1640 media supplemented with 2%
penicillin-streptomycin, 5% L-glutamine, and 5% fetal bovine serum (Gibco,
Grand Island, NY) at a cell density of 1 X 106 cells/ml at 37°C in a 5% CO2
atmosphere, with the exception of the RNK-16 cell line, which was also
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supplemented with 1% nonessential amino acids and 5 X 10-5 M 2-Bmercaptoethanol (Gibco ). The murine macrophage cell line P388Dl (ATCC,
Rockville, MD), was incubated for 4 hr with 10 µg/ml LPS (Difeo, Detroit, MI)
and used as a positive TNFa mRNA control. The rat NK cell line RNK-16 (a gift
from Dr. C. Reynolds, NIH, Frederick, MD), was cultured for 18 hr in the
presence of 20 ng/ ml phorbol myristate acetate (PMA) and 1000 U / ml IL-2,
(Sigma, St. Louis, MO) and used as a negative TNFa mRNA control. Splenic
mononuclear cells (SMNCs) were isolated as previously described (Schneider
1984) from adult male Lewis rats and were cultured for 18 hr in the presence or
absence of 20 ng/ml PMA and 2 µg/ml phytohemagglutinin (PHA), and used as
postive and negative LT mRNA controls, respectively. After incubation with
respective mitogens, cells were collected and processed for RNA as described
below.
RNA Blot Analysis
For Northern blot analysis, total cellular RNA was prepared from cells
and tissues by homogenization using a Brinkmann polytron (Brinkmann
Instruments, Inc., Westbury, NY) in the presence of guanidinium isothiocyanate
(Chirgwin et al., 1979). RNA was quantitated spectrophotometrically using O.D.
260 nm determinations (Maniatis et al., 1989). After electrophoretic separation in
a 1.0% formaldehyde agarose gel, RNA was applied by Northern transfer
(Thomas, 1980) to Nytran filters (Schleicher & Schuell, Keene, N.H.). Filters were
baked at 80°C for 1 hr and prehybridized in a solution containing 50%
formamide and 10% dextran sulfate for 4 hr at 42°C. Filters were then hybridized
overnight at 42°C in a solution containing either a TNFa cDNA probe prepared
using the 1.7 kb murine TNFa sequence cloned into the PstI/BamHI site of
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pUC9 vector, (a gift from Chiron Corporation, Emeryville, CA) (Pennica et al.,
1985), or an LT probe prepared using the 0.71kb Kpnl/Hincll fragment of the
1.42 kb murine LT cDNA sequence (a gift from Dr. N. Ruddle, Yale University,
New Haven, CT) (Li et al., 1987). Probes were radiolabeled with [32p] a-dATP as
described elsewhere (Feinberg & Vogelstein, 1983), using the Prime-a-Gene
labeling system (Promega, Madison, WI), and used at 2 x 10 6 cpm/ml of
hybridization solution. Hybridized filters were subsequently washed at room
temperature (2 X 15 min) in 2X SSC and 0.1 % sodium dodecyl sulfate, and then at
55°C (2 X 15 min) in 0.2X SSC and 0.1 % sodium dodecyl sulfate, after which the
filters were air-dried and autoradiographed using Kodak XAR-5 x-ray film with
intensifying screens at-70° C.

Protein Assays
Cardiac graft tissue homogenates were prepared using a Brinkmann
polytron (Brinkmann Instruments) in 1.5 ml phosphate-buffered saline
containing 2 mM phenylmethylsulfonyl fluoride (PMSF) protease inhibitor
(Sigma) for analysis of TNF protein. Tissue homogenates were briefly
centrifuged in a microcentrifuge to remove excess particulate matter.
Supernatants were then concentrated approximately 10-fold using Centricon-10
microconcentrators (Amicon, Beverly, MA). The samples were kept on ice for the
duration of the assay and subsequently stored at-70° C. Total protein levels
were quantitated using a modification of the Lowry colorimetric procedure
(Sigma). Tissue samples were standardized to 150 µg total protein per well and
assayed in duplicate for TNF immunoreactive protein using an ELISA (enzyme
linked immunosorbent assay) system containing a hamster antimouse TNFa
antibody (Genzyme, Boston, MA). Results were analyzed
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spectrophotometrically using a MR600 microplate reader (Dynatech
Laboratories, Chantilly, VA) and TNF levels were expressed as pg/ml and U /ml

± S.E.M., using recombinant mouse TNFa as the standard (Genzyme ).
Statistical Analysis
Experimental groups were compared using a two way analysis of
variance for the existence of significant interaction between experimental group
and day post-tx. Differences were considered to be statistically significant at p _::; _
0.05.
Results

In order to determine cardiac graft viability, both isograft and allograft
tissues were monitored daily for ECG and pulsatile activity. Representative ECG
recordings from isografts at six different time points (days 2, 7, and 10, and at 1,
4, and 12 months) post-tx are shown in Figure 8. Isograft tissue demonstrated
regular and progressively stronger ECG activity when measured on days 2, 7,
and 10 post-tx, with the average heart rate increasing by almost two-fold from
day 2 to day 10 post-tx (Figure 8). In addition, an increase in heart rate up to one
month post-tx was observed in isografts, at which time they tended to reach a
steady rate of ECG activity. In isografts monitored up to 1 year post-tx, graft
heart rate appeared to approach approximately 50% of the intrinsic heart rate of
the animals (Figure 8). The average intrinsic heart rate of a rat was found to
average 350 bpm, and differences in the two isograft combinations used, DAinto-DA and Lewis-into-Lewis were not significant (data not shown).
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In comparison, ECG recordings from cardiac allograft tissue on days 2, 7,
and 10 post-tx demonstrated diminished electrical activity with time post-tx,
indicating graft failure as defined by absence of detectable bpms (Figure 9). On
day 2 post-tx, the average heart rate for allografts was 77.97 ± 10.3 bpm, which
was not statistically significant when compared with the average isograft rate on
the same day (Table 1). However, by day 7 post-tx the allograft rate decreased to
64.83 ± 9.1 bpm, in contrast to an increased heart rate of 121.43 ± 16.7 observed in
isografts. These findings represented a statistically significant difference in
allograft heart rate on day 7 post-tx, as compared with control isografts (p _::;_
0.002). Isograft heart rates remained relatively constant at day 10 post-tx at
143.14 ± 19.9, while allograft rates continued to decrease with time, such that by
day 10 post-tx, ECG and pulsatile activity of cardiac allografts were virtually
undetectable. In all but one case, the heart rate of allografts on day 10 post-tx
were Obpm (Table 1). It was determined in the course of these studies that the
average time to rejection of cardiac transplants in allograft recipients was 7 days.
Both allograft combinations used, DA-into-Lewis and BN-into-Lewis, yielded
similar results (data not shown).

TABLE 1.

Cardiac graft viability post-transplantation
Day post-TX
2

Allograft (bpm)

77.97 ± 10.3
(n = 32)

64.83 ± 9.1
(n = 29)

10
b
(n = 23)

Isograft (bpm)

75.60 ± 9.4
(n = 25)

121.43 ± 16.7
(n = 21)

143.14 ± 19.9
(n = 22)

a P _::;_ 0.002

b All values except for 1 (n = 22)

= 0.00.
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Fig. 8. Long-term cardiac isograft viability as determined by ECG recordings.
Representative ECG recordings from six different time points post-tx are shown.
All recordings were performed at a constant chart speed of 5.0 mm/ sec; bpm,
beats per minute.
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Fig. 9. Comparison of cardiac isograft and allograft viability. Representative
ECG recordings from three different time points post-tx are shown. All
recordings were performed at a constant chart speed of 5.0 mm/ sec; bpm, beats
per minute.
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Expression of the cytotoxic cytokine genes TNFa and LT was examined
in cardiac transplants at various times post-tx. Cardiac graft tissue was analyzed
for the presence of TNFa mRNA on days 1-10 post-tx by Northern blot analysis
(Figure 10). Expression of TNFa in cardiac allografts appeared to be biphasic
(Figure lOA). Peak levels of TNFa mRNA appeared on day 3 post-tx, and
although levels decreased by day 4 post-tx, an increase in TNFa mRNA appeared
again on day 6 or 7 post-tx, coinciding with graft rejection as measured by ECG
activity (Figure 9). Detectable levels of TNFa gene expression were absent in
RNA samples prepared from cardiac isografts (Figure lOB).

Cardiac transplants were also analyzed for LT mRNA levels on days 1
through 10 post-tx by Northern blot analysis (Figure 11). Similar to TNFa gene
expression in cardiac allografts, LT demonstrated a biphasic pattern of
expression (Figure llA). Peak levels of LT mRNA in cardiac allografts were
observed on day 3 post-tx, with a second increase in LT transcript levels
occurring later, coincident with graft rejection. No detectable levels of LT gene
expression were found on days 1 through 10 post-tx in RNA samples prepared
from cardiac isografts (Figure llB).
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Fig. lOA. TNFa mRNA levels in cardiac allografts. Total RNA isolated from
cardiac allografts retrieved on days 1-10 post-tx were examined by Northern blot
analysis for TNFa gene expression. Representative Northern blot is shown
above. As with Fig. lOB, the murine monocyte cell line, P388D1, stimulated in
vitro with LPS (10 µg/ml) for 4 hr was used as a positive TNFa mRNA control.
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Fig. lOB. TNFa mRNA levels in cardiac isografts. Total RNA isolated from
cardiac isografts retrieved on days 1-10 post-tx were examined by Northern blot
analysis for TNFa gene expression. Representative Northern blot is shown
above. The rat NK cell line, RNK-16, stimulated in vitro with a PMA (20
ng/ml)/IL-2 (1000 U/ml) combination served as a negative control for TNFa
mRNA expression. As with Fig. lOA, blots were prepared using 15 µg of total
RNA per lane; autoradiogram exposure time was 18 hr. Ethidium bromide
staining of 18S and 28S ribosomal RNA subunits is included to illustrate
standardized lane loading and intact, nondegraded cellular RNA. Kb, kilobases.
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Fig. llA. LT mRNA levels in cardiac allografts. Total RNA isolated from cardiac
allografts retrieved on days 1-10 post-tx were examined by Northern blot
analysis for LT gene expression. Representative Northern blot is shown above.
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Fig. llB. LT mRNA levels in cardiac isografts. Total RNA isolated from cardiac
isografts retrieved on days 1-10 post-tx were examined by Northern blot analysis
for LT gene expression. Representative Northern blot is shown above. SMNCs
isolated from adult male Lewis rats and stimulated in vitro with a combination of
PMA (20 ng/ml) and PHA (2 µg/ml) for 18 hr were used as a positive control,
and untreated SMNCs were used as a negative control for LT mRNA. As with
Fig. 1lA, blots were prepared using 15 µg of total RNA per lane; autoradiogram
exposure time was 5 days. Ethidium bromide staining of 18S and 28S ribosomal
RNA subunits is included to illustrate standardized lane loading and intact,
nondegraded cellular RNA. Kb, kilobases.
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In order to determine whether TNF protein levels paralleled the
observed changes in mRNA, an ELISA method was used to quantitate TNF
protein in transplanted cardiac tissues. TNF protein levels in cardiac allografts
were significantly increased over cardiac isografts as early as day 2 post-tx
(Figure 12). TNF protein demonstrated a biphasic pattern, similar to that shown
for TNFa and LT mRNA in cardiac allograft tissues on day 3 post-tx, with 4-fold
greater levels in allografts (approximately 400 pg/ml or 16.5 U /ml; 1 U = approx.
24.3 pg) compared to isografts, and a second increase in TNF appeared in
allografts on day 6 post-tx. In contrast, TNF protein levels in cardiac isografts
were at or below standard limits of detection (50 pg/ml) at all other times posttx, and were significantly decreased on days 3 through 7 when compared with
time-matched cardiac allografts (p ~ 0.001).
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Fig. 12. TNF protein levels in cardiac transplants. Cardiac isograft and allograft
tissues were retrieved on days 1-10 post-tx and analyzed for TNF protein,
expressed as pg/ml and U/ml (1 U = approx. 24.3 pg)± SEM. Data shown are
mean values of four experiments performed with different allograft and isograft
tissue samples. TNF protein levels in cardiac allografts were significantly
increased when compared to cardiac isografts (p ~ 0.001).
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Discussion

In the present study using a heterotopic method of cardiac transplantation
into the rat ear, we have demonstrated that cardiac allografts, but not isografts,
undergo acute rejection by day 10 post-tx. Serial recordings of ECG activity
indicate that the average day to rejection of cardiac allografts is Day 7 post-tx, at
which time the average allograft heart rate has significantly decreased by twofold, when compared to the average heart rate of day-matched isografts. These
findings are consistent with earlier reports assessing rat cardiac allograft rejection
by cessation of palpable pulsatile activity (Tilney et al., 1978; Hancock et al., 1991;
Scheringa et al., 1991). Furthermore, average allograft heart rates are found to
continually decrease, such that by day 10 post-tx ECG activity is undetectable. In
contrast to allograft activity, average isograft heart rates demonstrate regular
ECG and pulsatile activity up to 1 year post-tx. Although palpable cardiac
contractility may determine day of rejection, monitoring ECG activity allows for
qualitative and quantitative analysis of relative graft viability.

Rat cardiac allografts, but not isografts, indicate significant increases in
TNFa and LT mRNA and protein levels between days 1 through 10 post-tx. We
have found that both TNFa and LT gene expression reach peak levels in situ
early after allografting, usually on day 3 post-tx. Levels of these cytotoxic
cytokines decrease subsequently and rise again later post-tx, coincident with
graft rejection. The relative contributions of TNFa and LT proteins could not be
assessed since the TNFa antibody used in the ELISA procedure can not
distinguish between these two cytokine proteins (Sheehan et al., 1989). Since the
TNFa antibody was elicited using recombinant mouse TNFa (Sheenan et al.,
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1989), and results were obtained using a recombinant mouse TNFa standard,
values of TNF protein in rat cardiac transplants reported in these studies may
therefore be underestimated.

Interestingly, the second increase in both TNFa and LT expression is
consistently of lesser magnitude when compared with the first peak of
expression, but it appears to be allograft-specific. The significance of the early
rise in these cytotoxic cytokines post-tx is unknown. However, since this
elevation in TNF gene expression is noted in both allograft and isograft tissues,
we speculate that at least part of the first rise may be attributed to postsurgical
inflammatory (i.e., nonallospecific) events. Furthermore, the significantly greater
early TNF response noted in allografts may reflect allospecific events, such as
endothelial cell activation (Collins et al., 1986) and increased migration and
adhesion of leukocytes (Shalaby et al., 1985).

These results demonstrating the presence of TNF in rat cardiac allografts
are in accordance with recent observations reporting marked elevations in
circulating TNFa in patients undergoing allograft rejection (Maury & Teppo,
1987; Chollet-Martin et al., 1990), as well as in situ in allografted tissues
(Arbustini et al., 1991; Krams 1989). Likewise, increased circulating levels of LT
have also been detected in patients (McKenna et al., 1988; Dallman et al., 1991)
and animal models of allograft rejection (Lowry et al., 1985b). However, our
attempts to measure circulating levels of TNF in the transplant model used in the
present study have consistently indicated levels at or below the limits of
detection (50 pg/ml), even in allograft recipients. Results obtained from the
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present study, however, indicate that both TNFa and LT levels are significantly
elevated post-tx in allograft tissues relative to isograft controls.

Although the present study and others report elevated levels of TNFa and
LT during allograft rejection, the actual roles of these two cytotoxic cytokines in
rejection are less well defined. They may participate in the rejection process by
indirect activation of leukocyte subpopulations or by direct lytic mechanisms.
One possible source of TNF may be activated mononuclear phagocytes in the
heart graft, since it has been reported that TNFa is released by cells of the
monocyte/macrophage lineage in infiltrating rejecting rat cardiac allografts
(Lowry & Blais, 1988). Another contributing source, although possibly not the
primary source, may be activated peripheral T lymphocytes, which have recently
been shown to synthesize TNFa (Steffen et al., 1988).

At least one report indicates that elevated TNF levels in serum coincides
with clinical rejection (Maury & Teppo, 1987). The present studies, however,
indicate significant elevations in graft TNF levels well in advance of transplant
rejection. It has been reported that rat cardiac allografts elicit a biphasic cellular
immune response, with the second phase coinciding with the time of acute graft
rejection (Tilney et al., 1978); these findings are consistent with the increases in
TNF levels observed in the present study.

The present study supports a role for both TNFa and LT cytotoxic gene
products in the pathogenesis of allograft rejection and indicate that elevated
levels of TNFa/LT may act as early indicators of incipient graft rejection. Studies
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such as these are designed to elucidate the pathophysiological mechanisms
involved in graft rejection and may lead to more effective strategies aimed at
promoting graft success.
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CHAPTER3
USE OF LOW DOSE CYCLOSPORINE A/METHOTREXATE TO PROLONG
RAT CARDIAC ALLOGRAFT SURVIVAL

Abstract

CSA is the standard immunosuppressive treatment used in human
cardiac transplantation to prevent rejection; however, adverse side effects have
been reported at therapeutic doses. Therefore, a need remains for the
implementation of specific therapies designed to achieve transplant success with
a minimum of undesirable side effects. The aims of the present study were: 1)
to evaluate the efficacy of a low dose CSA (1.0 mg/kg/ day)/ MTX (450
µg/kg/wk) combination therapy in prolonging rat cardiac allograft survival, and
2) to determine the effects of low dose CSA/MTX on IL-2 gene expression in rat
cardiac allografts. The average time to rejection of newborn donor BN rat hearts
transplanted into the ear pinnae of CSA/MTX-treated adult Lewis recipients,
measured by the absence of ECG activity, more than doubled from day 8 post-tx
to day 18 post-tx when compared to allografts in untreated control recipients (p ~
0.01). Northern blot analysis demonstrated that IL-2 mRNA transcripts in
cardiac allografts treated with low dose CSA/MTX were detected as early as day
1 post-tx, and at increasing levels as rejection progressed post-tx. When IL-2
gene expression in allografts from CSA/MTX treated recipients was compared to
levels in allografts from untreated recipients, no significant difference in the
pattern of IL-2 induction was observed. In contrast, IL-2 mRNA transcripts were
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not detected post-tx in allografts from recipients treated with high-dose (15
mg/kg/ day) CSA or in cardiac isografts. The presence of IL-2 gene transcripts,
therefore, appears to be allograft-specific. Furthermore, low dose CSA/MTX
therapy does not appear to prolong transplant survival by altering steady-state
levels of IL-2 gene transcripts. We conclude that low dose CSA/MTX treatment
may serve as a possible alternative immunosuppressive therapy for promoting
allograft survival while minimizing high dose CSA side effects. Further studies
are required to elucidate the mechanism(s) by which low dose CSA/MTX
combination therapy increases the time to rat cardiac allograft rejection.
Introduction

Using a heterotopic method of cardiac transplantation into the rat ear
(Fulmer et al., 1963), we have previously demonstrated that cardiac allografts but
not isografts undergo acute rejection by day 10 post-tx, with the average time to
rejection being day 7 post-tx (Pizarro et al., 1993a). In this model, we have found
that significant increases in TNFa and LT mRNA and protein levels occur
between days 1 through 10 post-tx in rat cardiac allografts but not isografts
(Pizarro et al., 1993a). These studies support a role for both TNFa and LT
cytotoxic gene products in the pathogenesis of allograft rejection. The objective
of the present study is to determine if a combination low CSA/MTX
immunosuppressive therapy administered to allograft recipients has the ability
to prolong survival of rat cardiac transplants compared to untreated controls,
using the aforementioned model.
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CSA is a cyclic endecapeptide derived from the soil fungus, Tolypocladium
inflatums, and has been demonstrated to be a potent immunosuppressive agent

and inhibitor of helper T function (Borel et al., 1976; Orosz et al., 1983). CSA was
first introduced in human transplantation over a decade ago (Caine et al., 1978),
and since that time has become the immunosuppressive agent of choice
following organ replacement. Although CSA has been used with considerable
success clinically to prolong organ graft survival (Caine et al., 1978; CostanzoNordin et al., 1990), significant adverse side effects, such as nephrotoxicity
(Myers et al., 1984), hepatotoxicity (Vine et al., 1988), hypertension (Munoz et al.,
1988), as well as neurological toxicities (deGroen et al., 1987) have been reported
with its use.

Since the landmark findings which first described CSA's ability to
suppress cell-mediated immunity (Borel et al., 1976), numerous investigations
have examined the mechanism(s) of action of CSA and have consistently
demonstrated the inhibition of IL-2 gene transcription by CSA (Kronke et al.,
1984; Elliot et al., 1984). The main focus in attempting to elucidate CSA's
immunosuppressive action has centered on the direct effects of CSA upon CD4 +
helper T lymphocytes; one functional characteristic of CD4+helper T cells is the
synthesis and subsequent release of a range of several cytokines, including IL-2.

IL-2 has been demonstrated to induce the differentiation and clonal

expansion of mature T lymphocytes and appears to be an important mediator of
allograft rejection, since a positive correlation between IL-2 levels and rejection
episodes has been described (Yoshimura & Kahan, 1985; Vie et al., 1985;
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McKenna et al., 1988). In addition, anti-lL-2 receptor antibodies have been shown
to prevent allograft rejection in experimental models (Kirkman et al., 1985). CSA
is thought to act as an immunosuppressive agent through potent inhibition of IL2 production by T cells (Kronke et al., 1984; Elliot et al., 1984).

Since CSA at therapeutic doses may exert profound physiologic changes
in addition to its immunosuppressive properties, these changes often result in
toxic side effects (Myers et al., 1984; Vine et al., 1988; Munoz et al., 1988;
deGroen et al., 1987). Therefore, a need remains for implementing specific
therapies directed at achieving transplant success with a minimum of
undesirable sequelae. One approach is the utilization of combination treatments
at lower therapeutic doses, which may result in increased survival time of organ
transplants, while minimizing adverse side effects.

MTX is classified pharmacologically as an antimetabolite because of its
antagonistic effect on folic acid metabolism and function (Mitchell et al., 1969).
MTX binds to dihydrofolate reductase which results in the inhibition of DNA
synthesis; this antiproliferative action has made MTX a useful drug for cancer
chemotherapy (Jolivet et al., 1983). Immunosuppressive effects have also been
attributed to MTX (Mitchell et al., 1969), and its utilization in the treatment of
rheumatoid arthritis, for example, has demonstrated both long term and short
term efficacy (Weinblatt et al., 1985; Perhala & Wilke, 1991). The mechanism(s),
however, by which MTX suppresses disease activity in inflammatory rheumatoid
arthritis is still poorly understood and adverse side effects, such as severe
leukopenia and gastrointestinal upset, have been associated with the use of MTX
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(Weinblatt et al., 1985). It has been suggested that MTX may exert its
immunosuppressive action by deactivation of macrophages, resulting in
decreased IL-1 production (Hu et al., 1988), as well as by inhibition of
macrophage migration, resulting in decreased accumulation of inflammatory
cells and/ or immune mediators (Johnson et al., 1988). Conversely, the
administration of MTX restored both T cell function (Kourounakis & Kapusta,
1976) and IL-2 production (Combe et al., 1985) in rheumatoid arthritis.

Recently, MTX has also shown favorable results in treating persistent
mild (Olsen et al., 1990), as well as recurrent moderate to severe cardiac allograft
rejection (Costanzo-Nordin et al., 1988). Success has also been demonstrated
using CSA at doses of 10-15 mg/kg/ day combined with either high or low dose
MTX in the prevention of graft-versus-host disease after bone marrow
transplantation in experimental animal models (Deeg et al., 1982; Deeg et al.,
1984), as well as in human clinical studies (Storb et al., 1986; Truog & Wozniak,
1990). These data strongly suggest that administration of a low dose CSA/MTX
combination therapy may serve as a possible alternative treatment in promoting
cardiac allograft survival while minimizing both high dose CSA and MTX side
effects.

The purpose of the present study was to evaluate the efficacy of low dose
CSA (1.0 mg/kg/ day) / MTX (450 µg/kg/wk) combination therapy in
prolonging rat cardiac allograft survival and to determine the effects of low dose
CSA/MTX on IL-2 gene expression in rat cardiac allografts. Studies such as
these may provide a basis for the implementation of combination
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immunosuppressive therapies leading to improvements in post-transplantation
management.
Materials, Methods and Experimental Design

Animals
Pregnant BN and Lewis, and six to eight-week-old male Lewis rats were
purchased from Harlan Sprague Dawley (Harlan Sprague Dawley, Indianapolis,
IN). All animals received water and food ad libitum, and were housed in

accordance with institutional animal care and use guidelines. Adult male Lewis
rats served as recipients of donor cardiac tissue obtained from either one to threeday-old Lewis or BN rats, which served as isograft and allograft groups,
respectively. The donor ages used have been previously reported to result in
optimum isograft viability (Fulmer et al., 1963) and were of appropriate size so
that the whole heart grafts might be accommodated by the recipients' ears.
Cardiac Transplantation
The procedure utilized was a modification of the heterotopic method of
cardiac transplantation into the mouse ear as described by Fulmer et al (1963)
(Figure 6). Cardiac graft recipients were anesthetized with i.p. injection of
ketamine/xylazine (20:1) (Fort Dodge Laboratories, Fort Dodge, IA and Rugby
Laboratories, Inc., Rockville Centre, NY) at 105 mg/kg body weight prior to
surgery. The dorsal surface of the recipient's ear pinna was nicked at the
proximal end with a sterile scalpel and a subcutaneous pouch was prepared
using blunt forceps. At the time of donor sacrifice, whole newborn hearts were
harvested promptly and gently inserted into the ear pouches of the recipients. In
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order to prevent graft loss and promote revascularization, skin flaps surrounding
the graft site were apposed by applying gentle pressure with forceps. Each
recipient was grafted bilaterally, one whole heart per recipient ear, with either
two isografts or allografts per animal. Cardiac graft recipients were anesthetized
with ketamine and monitored daily by visual inspection for pulsatile activity and
by electrocardiography using pin electrodes placed on either side of the graft
with leads connected to a polygraph recorder (Grass Model 79D, Grass
Instruments Co., Quincy, MA) (Figure 7).

Animal Treatment Groups
Lewis cardiac allograft recipients were injected i.p. with CSA in olive oil
vehicle once daily, beginning on the same day of transplantation (day 0), and/or
MTX in saline vehicle once weekly, beginning one week prior to the day of
transplantation, as follows. Allograft recipients were placed in one of five
treatment groups consisting of either high dose CSA (15 mg/kg/ day), low dose
CSA (1 mg/kg/ day), low dose MTX (450 µg/kg/wk), combination low dose
CSA/MTX treatment (1 mg/kg/ day and 450 µg/kg/wk, respectively), or control
treatment group (saline and olive oil vehicles according to the aforementioned
protocol). All allograft recipients received treatment through day 7 post-tx.
Cardiac transplants were monitored daily for pulsatile and ECG activity as
described above for graft survival, with retrieval of one graft per recipient
occurring on days 3 through 8 post-tx for each treatment group; cardiac grafts
were processed for total cellular RNA as described below. Subsequent to these
studies, a second treatment group consisting of low dose CSA/MTX combination
therapy was prepared to permit graft retrieval at eight time points, days 1
through 8 post-tx, for RNA analysis.
64

Cell Culture
SMNCs were isolated from adult male Lewis rats by centrifugation of
spleen tissue suspensions through a Ficoll density gradient (Lymphocyte
Separation Medium (LSM), Organon Teknika, Durham, NC), as described in an
earlier report (Pizarro et al., 1993a). SMNCs were cultured in RPMI-1640 medium
supplemented with 2% penicillin-streptomycin, 5% L-glutamine and 5% fetal
bovine serum (GIBCO, Grand Island, NY) at a cell density of 1 X 106cells/ml at
37°C in 5% CO2 in air, either in the presence or absence of a 20 ng/ml PMA and 2
µg/ml PHA combination for 18 hr and used as positive and negative controls for
IL-2 mRNA, respectively. After incubation with or without mitogen stimulation,
cells were collected and processed for RNA as described below.

RNA Blot Analysis
For Northern and slot blot analysis, total cellular RNA was prepared
from cells and tissues by acid guanidinium thiocyanate-phenol-chloroform
extraction (Chomczynski & Sacchi, 1987), and blots were prepared as described
previously (Pizarro et al., 1993a). Filters were hybridized with an IL-2 cDNA
probe prepared using a 900 b.p. murine IL-2 insert cloned into the BamHI site of
pCD vector, (a gift from Dr. Ken-ichi Arai, DNAX Research Inst., Palo Alto, CA)
(Kashima et al., 1985) and prepared for autoradiography as previously described
(Pizarro et al., 1993a).
Statistical Analysis
Experimental groups were compared using analysis of variance and
multiple regression analysis for the existence of significant differences between
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treatment and control groups. Differences were considered to be statistically
significant at p 5. 0.05.

Results

In order to determine cardiac graft viability, tissues transplanted in
allograft recipients from the four experimental treatment groups (N=6) and
control group (N=7) were monitored daily for ECG and pulsatile activity (Figure
7). Allograft rejection was defined by the absence of detectable ECG activity. In
untreated allograft recipients, absence of ECG activity was noted on either day 6
or 7 post-tx in five of the seven cardiac allografts. ECG activity was undetectable
in the two remaining grafts by day 10 post-tx; the average time to allograft
rejection in the control group was determined to be day 7.4 ± 0.68 post-tx (Table
2).

TABLE 2. Cardiac allograft survival time post-transplantation
DAY POST-TX
RECIPIENT#

TREATMENT
1

2

3

4

5

6

7

RANGE

MEAN±S.E.M

HIGHCSAl

18* 12* 36

21* 36

36

-

21-36

32.3 ± 3.75

CSA/MTX 2

18

17 18

18 18

18

-

17 -18

17.8 ± 0.16

LOWCSA 3

14

14

12

14

14

12

-

12 -14

13.3 ± 0.42

MTX 4

10

10

10

14

8

8

-

8-14

10.0 ± 0.89

6

6

10

7

6

10

7

6-10

7.4 ± 0.68

CONTROLS

* Expired due to anesthesia complications.
1-4N = 6
5 N=7
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High dose CSA-treated recipients demonstrated the longest survival time
of cardiac allografts when compared to control and other treatment groups (day
32.3 ± 3.75). Figure 13 summarizes these data in graph form by depicting the
proportion of surviving cardiac allografts in control and experimental treatment
groups, and comparing transplant survival time (day post-tx) among the
different groups. The incidence of death due to failure to recover from
anesthesia administered for ECG measurements, however, was increased in the
high dose CSA-treated group (three of the six recipients expired while under
anesthesia during graft monitoring on days 12, 18, and 21 post-tx). Cardiac
allograft tissue transplanted in combination low dose CSA/MTX-treated
recipients demonstrated significantly increased survival time post-tx (average
time to rejection was determined to be day 17.8 ± 0.16), when compared to
untreated controls (p .5. 0.01), without apparent complications due to anesthesia
during graft monitoring (Table 2, Figure 13). In fact, all but one (rejection by day
17 post-tx) of the combination low dose CSA/MTX-treated recipients
demonstrated rejection of cardiac allografts at day 18 post-tx, a two and one-halffold increase in allograft survival time over untreated controls.

Furthermore, cardiac transplants in low dose CSA alone-treated recipients
showed a significant increase in allograft survival time post-tx when compared to
control (average time to rejection was 13.3 ± 0.42 days); however, this increase
was found to be comparatively less than that found in heart allografts
transplanted into low dose CSA/MTX-treated recipients (p .5. 0.05) (Table 2,
Figure 13). Cardiac allografts in MTX alone-treated recipients did not show a
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significant difference in graft survival time post-tx (average time to rejection was
10.0 ± 0.89 days) compared to control (Table 2, Figure 13).

1
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- - - - LOWDOSECSA
- - - - MTX

z
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- - - - CONTROL
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~

0
~
0

0.2

~

~

0

0
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24

28

32

36

DAY POST-TX

Fig. 13. Survival curves for cardiac allograft control and experimental treatment
groups. All control (N=7) and treatment (N=6) groups were assessed for graft
viability by serial ECG recordings post-tx. Allograft rejection was defined by the
absence of detectable ECG activity. Results are reported as the proportion of
surviving cardiac allografts in control and experimental treatment groups with
time post-tx. Cardiac allograft survival was significantly prolonged in recipients
treated with high dose CSA (p ~ 0.001), low dose CSA/MTX (p ~ 0.01), and low
dose CSA (p ~ 0.05), when compared to untreated allograft recipients.

In addition to daily monitoring of allograft viability, the intrinsic heart
rates of control and treated recipients were also measured (Figure 7). As shown
in Table 3, the intrinsic heart rate of all cardiac allograft recipients was
significantly greater than graft heart rates at all times monitored, regardless of
treatment of the recipient. The intrinsic heart rate of the recipient was found to
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average approximately 425 bpm, with no significant differences among treatment
groups (Table 3).

In comparison to intrinsic heart rates, a decrease in the average heart rate
of cardiac allografts was observed with time post-tx, which was dependent on
the treatment given to the recipient. All cardiac allografts demonstrated similar
heart rates up to day 3 post-tx, after which gradually diminishing as well as
irregular ECG activity was demonstrable, indicating incipient graft rejection
(Table 3). Allografts from untreated recipients showed more than a two-fold
decrease in heart rate from day 3 to day 6 post-tx, from 107.14 ± 11.5 to 41.82 ±
8.9 bpm (Table 3). As mentioned previously, absence of detectable ECG activity
was noted on either day 6 or 7 post-tx in five of the seven untreated control
cardiac allografts, with the two remaining grafts losing ECG activity by day 10
post-tx (Table 2).

Heart rates measured in cardiac allografts transplanted into low dose
CSA/MTX-treated recipients on days 3 ,6 ,8, and 10 post-tx were found to have
distinct and regular heart rates of 82.72 ± 8.2, 130.00 ± 20.7, 133.33 ± 15.6, and
122.33 ± 11.6, respectively (Table 3). However, by day 14, a decrease in allograft
heart rate (62.00 ± 19.3, Table 3) was noted in low dose CSA/MTX-treated
recipients. A further decrease was reported with time, such that in all but one
case, ECG and pulsatile activity were virtually undetectable by day 18 post-tx
(Table 2). This finding, however, represented more than a two-fold increase in
cardiac allograft survival in low dose CSA/MTX-treated recipients when
compared to untreated controls (p ~ 0.01).
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Graft heart rate in cardiac allografts transplanted into low dose CSAtreated recipients decreased by day 10 post-tx (data not shown), with no
detectable ECG activity by day 14 post-tx (Table 3). Although graft survival time
was shorter than that found in low dose CSA/MTX-treatment, administration of
low dose CSA alone also showed prolongation of graft survival time by almost
one week post-tx, when compared to untreated controls (p ~ 0.05). Conversely,
in MTX alone-treated animals, graft heart rates showed diminished ECG and
pulsatile activity by day 6 post-tx (47.5 ± 11.1), which continued until day 10 or
11 post-tx, at which time no detectable ECG activity was measured (Table 3). No
statistically significant difference in allograft survival time was demonstrated in
cardiac allografts in MTX alone-treated recipients, as compared with untreated
controls.

Cardiac allografts in high dose CSA-treated recipients showed regular but
gradually diminishing heart rates through day 29 post-tx, at which time the
remaining three allografts demonstrated markedly diminished heart rates (Table
3, Figure 13); graft failure was noted by day 36, when no detectable ECG and
pulsatile activity were recorded (Table 3).
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TABLE 3. Cardiac heart rate post-transplant

DAY POST-TX

DAY3

TREATMENT

GRAFT INTRINSIC
RATE'
RATE

DAY6

DAYS

GRAFT
RATE

INTRINSIC
RATE

GRAFT
RATE

INTRINSIC
RATE

DAY14

GRAFT INTRINSIC
RATE
RATE

DAY18

GRAFT
RATE

INTRINSIC
RATE

DAY36

GRAFT
RATE

INTRINSIC
RATE

HIGH CSA
(N = 6) 2

85.00
+9.6

400.00
± 11.5

130.00
±18.3

406.67
±29.6

155.00
± 12.6

430.00
±.25.2

110.00
± 11.8

428.00
±21.5

92.50
± 16.5

365.00
±23.6

CSA/MTX
(N=6)

82.72
+ 8.2

457.70
±21.7

130.00
+20.7

412.50
± 12.5

133.33
+15.6

490.00
+29.2

62.00
+19.3

382.00
+29.4

*

456.00
+27.1

-

-

LOW CSA
(N = 6)

90.00
±12.9

433.00
±24.0

125.00
±18.5

376.66
±43.3

122.50
±6,3

426.66
± 17.6

*

385.00
±22.5

-

--

-

MTX
(N=6)

67.50
±14.9

466.67
±24.0

47.50
±11.1

426.67
± 17.6

24.28
±9.0

483.33
±37.6

-

-

-

-

-

-

CONTROL
(N=7)

107.14
±11.5

400.00
±28.9

41.82
±8.9

420.00
±41.6

*

446.67

-

-

-

-

-

-

*

410.00
±20.8

* No detectable ECG activity
1 Heart rate measured in bpm
2 For all treatment groups, N = number at Day 3 post-tx

Representative ECG recordings from cardiac allograft tissue from control
and experimental treatment groups at nine different time points (days 3, 6, 8, 10,
12, 14, 18, 29, and 36) post-tx are shown in Figure 14. Diminished electrical
activity with time post-tx was observed for transplanted cardiac allografts by day
8 in untreated control recipients, day 10 in MTX alone-treated recipients, day 14
in low dose CSA alone-treated recipients, day 18 in combination low dose
CSA/MTX-treated recipients, and day 36 in high dose CSA-treated recipients.
Diminished ECG and pulsatile activity, as well as a decrease in the amplitude
and regularity of heart rates, occurred a few days prior to actual rejection
indicating impending graft failure.
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Day 6
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Day 8
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45 bpm

0 bpm

Control

Fig. 14. Comparison of cardiac allograft viability in treated and untreated
recipients. Representative ECG recordings from nine different time points (day
3, 6, 8, 10, 12, 14, 18, 29, and 36) post-tx are shown (A on this page, B, and Con
the following pages). All recordings were performed at a constant chart speed of
5.0 mm/ sec; bpm, beats per minute.
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Fig. 14B.
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Fig. 14C.
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IL-2 mRNA levels were examined in cardiac allografts from untreated
control recipients and combination low dose CSA/MTX-treated recipients at
various times post-tx. IL-2 mRNA levels were also examined in cardiac isografts
transplanted into untreated recipients. Northern blot analysis of IL-2 gene
expression in untreated cardiac allografts appeared to increase with time post-tx
(Figure 15A). Although detectable transcripts were observed as early as day 1 or
day 2 post-tx, a significant increase in IL-2 mRNA levels appeared on day 3 posttx, as well as on days 7 and 8 post-tx, at which time graft rejection usually occurs
(Table 2, Figure 15A). IL-2 mRNA levels were also examined on days 1 through 8
post-tx in cardiac allografts transplanted into combination low dose CSA/MTXtreated recipients (Figure 15B). Similar to IL-2 gene expression in cardiac
allografts from untreated control recipients, IL-2 transcripts in low dose
CSA/MTX-treated cardiac allografts were detected at early times post-tx, with
increased IL-2 mRNA levels by day 3 post-tx. These levels of IL-2 mRNA
remained high, with the exception of day 6, through day 8 post-tx, coincident
with graft rejection in untreated allograft recipients. In contrast to untreated and
low dose CSA/MTX-treated allografts, Northern blot analysis of cardiac isografts
did not demonstrate detectable levels of IL-2 mRNA on days 1 through 8 post-tx
(Figure 15C). Similarly, IL-2 gene transcripts were not detected in rat cardiac
allografts transplanted into high dose CSA-treated recipients (Figure 15D).
However, no apparent differences, including a decrease in IL-2 transcript levels
on day 6 post-tx, were seen at the steady state level of IL-2 mRNA in rat cardiac
allograft tissues transplanted into untreated and low dose CSA/MTX-treated
recipients.
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Day Post-Tx
1

2

3

5

4

8

7

8

-

1.4 Kb
0.9 Kb

-

288

- 188

Fig. 15A. IL-2 mRNA levels in cardiac allografts transplanted into untreated
control recipients. Total RNA isolated from cardiac a'llografts retrieved on days
1-8 post-tx were examined by Northern blot analysis for IL-2 gene expression.
Representative Northern blot is shown above. As with Fig. 14B, 14C, and 14D,
blots were prepared using 15 µg of total RNA per lane; autogradiogram exposure
time was 18 hr. Ethidium bromide staining of 18S and 28S ribosomal RNA
subunits is included to illustrate standardized lane loading and intact, non
degraded cellular RNA. Kb, kilobases.
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Day Post-Tx

2

3

4

5

6

7

8

1.4 Kb
0.9 Kb

-

288

- 188

Fig. 15B. IL-2 mRNA levels in cardiac allografts transplanted into low dose
CSA/MTX-treated recipients. Total RNA isolated from cardiac allografts
retrieved on days 1-8 post-tx were examined by Northern blot analysis for IL-2
gene expression. Representative Northern blot is shown above. SMNCs, spleen
mononuclear cells.
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Day Post-TX

1

2

3

4

5

6

7

8
-

288

-

188
1.4 Kb
0.9 Kb

-

288

-

188

Fig. 15C. IL-2 mRNA levels in cardiac isografts transplanted into untreated
control recipients. Total RNA isolated from cardiac isografts retrieved on days 18 post-tx were examined by Northern blot analysis for IL-2 gene expression.
Representative Northern blot is shown above.
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Day Post-TX
5

6

7

8

36

- 288

188
1.4 Kb
0.9 Kb

288

188
1.3Kb

- 288

- 188
Fig. 15D. IL-2 mRNA levels in cardiac allografts transplanted into high dose
CSA-treated recipients. Total RNA isolated from cardiac allografts retrieved on
days 3-8 and 36 post-tx were examined by Northern blot analysis for IL-2 gene
expression. Representative Northern blot is shown above. Blot was
subsequently stripped and reprobed for GAPDH housekeeping gene expression
l.3Kb, (middle panel).
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Discussion

Both beneficial as well as adverse effects of CSA have been well
documented since its initial use as a potent immunosuppressive agent in clinical
transplantation (Caine et al., 1978). Adverse side effects, in particular
nephrotoxicity (Myers et al., 1984) and hepatotoxicity (Vine et al., 1988), have
restricted its use at therapeutic doses (between 10-15 mg/kg/ day) and have
initiated attempts into exploring combination low-dose therapies. In fact,
concurrent administration of CSA with azathioprine, corticosteroids, polyclonal
antilymphocyte globulins, and monoclonal antibodies, such as OKT3, are
combination immunosuppressive regimens currently used in patients to promote
cardiac allograft survival (McGoon & Frantz, 1992). However, along with CSA,
the aforementioned immunosuppressive agents when administered at
therapeutic doses, also possess side effects with potentially undesirable
consequences (McGoon & Frantz, 1992).

Immunosuppressive properties have been attributed to the
chemotherapeutic drug, MTX (Mitchell et al., 1969; Weinblatt et al., 1985; Perhala
& Wilke, 1991). High dose MTX has long been used for treatment of neoplastic

diseases and works by indirectly inhibiting DNA synthesis (Jolivet et al., 1983).
The primary clinical concern with the administration of therapeutic doses of
MTX (conventionally 10 mg/every other day), is bone marrow suppression,
which may result in leukopenia as well as initiate the impending risk of infection
(Weinblatt et al., 1985). Low dose MTX has been also used in the treatment of
rheumatoid arthritis and its efficacy appears to depend on immunosuppressive
activities (Weinblatt et al., 1985; Perhala & Wilke, 1991). Recently, low dose MTX
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has also been used in patients to control persistent mild, as well as recalcitrant
cardiac allograft rejection (Costanzo-Nordin et al., 1988), and in canine recipients
to prevent rejection of pulmonary allografts (Blumenstock et al., 1988). Therefore,
low dose MTX treatment (450 µg/kg/wk in the present study), maintains
immunosuppressive efficacy and has a markedly lower incidence of toxicity.

The present study, using a heterotopic method of cardiac transplantation
into the rat ear, has indicated that low dose CSA/MTX treatment, where average
day to rejection is day 18 post-tx, significantly prolonged cardiac allograft
survival over day-matched allografts transplanted into untreated control
recipients, where average day to rejection is day 7 post-tx. Treatment of cardiac
allograft recipients with combination low dose CSA/MTX immunosuppressive
therapy, therefore, more than doubled allograft survival time post-tx when
compared to untreated controls. No apparent complications due to anesthesia
administration at the time of cardiac monitoring were noted in this treatment
group, in contrast to high dose CSA-treated recipients. Contrary to cardiac
allograft viability, average isograft heart rates were previously shown to possess
regular ECG and pulsatile activity up to one year post-tx (Pizarro et al., 1993a).

The present study also showed that combination low dose CSA/MTX
treatment significantly increased graft survival compared to low dose CSA alone
as well as MTX alone-treatments. Cardiac allografts transplanted into MTX
alone-treated recipients did not show significant differences in graft survival
time post-tx when compared with allografts from untreated recipients. Although
cardiac allografts transplanted into low dose CSA-treated recipients
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demonstrated an increase in transplant survival time over untreated controls (p .$.
0.05), this increase was found to be less than that found in combination low dose
CSA/MTX-treated recipients (p .$. 0.01).

Low dose CSA treatment (2.0 mg/kg/ day) of allograft recipients reduces
T cell proliferative responsiveness, but is unable to sustain long-term cardiac
allograft survival (Stepkowski et al., 1989). Studies such as these suggest that low
dose CSA administration has the ability to prolong cardiac graft survival post-tx,
by activation of T cell suppressor function(s) and/ or by altering the T cell's
ability to proliferate. The present studies indicate that low dose CSA treatment,
while able to delay allograft rejection, does not have the efficacy of combination
low dose CSA/MTX in prolonging rat cardiac allograft survival. The possibility
exists that MTX may provide additional immunosuppressive capabilities by
affecting T cell function and/ or regulating other cells participating in the
immune response.

Although the mechanism(s) by which MTX appears to exert
immunosuppression is still poorly understood, it is believed that MTX may
possess primarily anti-inflammatory activity due to rapidly occurring palliative
effects (Weinblatt et al., 1985). Indeed, animal studies support an antiinflammatory mechanism of action for MTX. In a murine model of adjuvantinduced arthritis, MTX inhibited hind paw edema, the activation of macrophages
by PGE2, the influx of MHC class II and macrophages into synovial tissue, and
IL-1 production (Hu et al., 1988). The findings that low dose MTX prevents
occurrence of arthritis induced by Freund's adjuvant in the rat, but fails to inhibit
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cyclo-oxygenase or 5-lipoxygenase, has been interpreted as evidence for
immunomodulation (Stepkowski et al., 1989). Furthermore, production of IL-1
and induction of primary delayed-type hypersensitivity were inhibited in MTXtreated rodents (Hu et al., 1988; Gibbons & Lucas, 1989). Therefore, in the
present study, the possibility exists that significant prolongation of cardiac
allografts transplanted into combination low dose CSA/MTX-treated recipients
may be due, in part, to the combined immunosuppressive actions of low dose
CSA primarily at the T cell level and MTX primarily at the macrophage effector
cell level.

In the present study, IL-2 mRNA levels in cardiac tissue was examined to
determine whether combination low dose CSA/MTX treatment, like high dose
CSA therapy, exerts its immunosuppressive action by altering steady state levels
of IL-2 mRNA. IL-2 gene transcripts were not detected in isografts or in rat
cardiac allografts transplanted into high dose CSA-treated recipients on any day
post-tx, when compared to allografts from untreated recipients. These findings
support previous reports that treatment with high dose CSA suppresses IL-2
gene transcription (Kronke et al., 1984; Elliot et al., 1984). No apparent
differences in IL-2 mRNA transcript levels were observed, however, between rat
cardiac allograft tissues transplanted into untreated and low dose CSA/MTXtreated recipients. IL-2 gene expression occurred early during the rejection
process, with IL-2 transcripts detected as early as day 1 or day 2 post-tx in heart
tissues transplanted in both low dose CSA/MTX-treated and untreated
recipients. Peak levels of IL-2 mRNA in cardiac allografts appeared early after
transplant, usually by day 3 post-tx, in both treated and untreated recipients. IL-
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2 mRNA levels remained elevated through day 8 post-tx, by which time allograft
rejection occurs in untreated recipients, as measured by the absence of detectable
ECG and pulsatile activity.

The present study reports an increased efficacy of low dose CSA/MTX
combination therapy in prolonging rat cardiac allograft survival when compared
to low dose CSA alone, low dose MTX alone, as well as untreated control
recipients. Unlike high dose CSA therapy, the mechanism(s) by which low dose
CSA/MTX prolongs allograft survival does not appear to be mediated by the
inhibition of IL-2 gene transcription. The possibility exists that low dose
CSA/MTX combination therapy may act on different effector cell populations
engaged in the allogeneic immune response. Further studies must address the
effects of low dose CSA and low dose MTX treatment alone on T-cell and
macrophage cytokine gene expression in rat cardiac allografts. Studies such as
these may provide new insight into the mechanisms of action of combination
therapies designed to promote transplant survival with minimal adverse side
effects.
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CHAPTER4
LOW DOSE CYCLOSPORINE A/METHOTREXATE COMBINATION
THERAPY LOWERS CYTOTOXIC GENE EXPRESSION IN RAT CARDIAC
TRANSPLANTS

Abstract

We have previously shown that administration of a combination
low dose CSA (1.0 mg/kg/ day) / MTX (450 µg/kg/wk) treatment significantly
increases the survival of rat cardiac allografts, and may therefore potentially
serve as an alternative immunosuppressive therapy designed to promote
transplant survival while minimizing high dose CSA side effects. In contrast to
high dose CSA, low dose CSA/MTX treatment does not appear to alter IL-2 gene
expression, since similar patterns of IL-2 gene transcripts were found in both low
dose CSA/MTX-treated and untreated control allografts on Days 1 through 8
post-tx. The mechanism(s) by which low dose CSA/MTX therapy increases the
time of allograft survival remains to be elucidated. The aim of the present study
was to determine the effects of low dose CSA/MTX on the expression of the
cytotoxic cytokines, TNFa, LT, and the serine proteases HF and Cll (granzymes
A and B, respectively) in rat cardiac allografts during rejection. RNA blot
analysis showed significant suppression of TNFa, LT, HF, and Cll gene
expression on days 1 through 8 post-tx in cardiac allografts from low dose
CSA/MTX-treated recipients compared to untreated allograft controls. TNF
protein levels in cardiac allografts from low dose CSA/MTX-treated recipients
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were also found to be significantly reduced on days 1 through 8 post-tx when
compared to time-matched untreated allograft controls (p ~ 0.001). We conclude
that low dose CSA/MTX treatment, while effective in prolonging cardiac
transplant survival, appears to act at the mRNA level to downregulate cytotoxic
gene expression. Such trials aimed at evaluating low-dose combination therapy
may afford new insight into mechanisms underlying improvement in
immunosuppressive treatment.

Introduction
We have previously shown that low doses of both CSA and MTX, when
used in combination, significantly increases the survival of rat cardiac allografts
(Pizarro et al., 1993b) and therefore may serve as an alternative
immunosuppressive therapy directed at promoting transplant survival. In
contrast to high dose CSA administration, combination low dose CSA/MTX
treatment does not appear to effect IL-2 gene expression. Similar levels of IL-2
gene transcripts have been found in cardiac allografts from both low dose
CSA/MTX-treated and untreated transplant recipients on Days 1 through 8 posttx (Pizarro et al., 1993b). In addition, significant increases in TNFa and LT
mRNA and protein levels have been shown to occur between days 1 through 10
post-tx in rat cardiac allografts transplanted into untreated recipients (Pizarro et
al., 1993a), supporting a role for both TNFa and LT in the pathogenesis of

allograft rejection. The need remains, therefore, to determine the mechanism(s)
by which low dose CSA/MTX combination therapy increases allograft survival
time compared to controls.
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After transplantation of a tissue allograft, an infiltrate consisting of several
cell phenotypes appears within the graft (Hanto et al., 1982). Both helper and
cytotoxic T lymphocyte infiltration precede the destruction of the transplanted
tissue by several days, and it is believed that these cells are paramount in the
process of allograft rejection (Loveland & McKenzie, 1982; Lowry et al., 1983).
Macrophages and NK cells have also been found to be components of the cellular
infiltrate in organ allografts undergoing acute rejection (Strom et al., 1977;
MacPherson & Christmas, 1984; Nemlander et al., 1983). These cells proliferate
and release cytokines which have been shown to damage blood vessels within
the graft (Dvorak et al., 1980), cause an increase in graft infiltration by leukocytes
(Cox et al., 1984), and stimulate the differentiation of graft-specific T cells at the
graft site (Heidecke et al., 1984). These local events mediated, at least in part, by
cytokines contribute to allograft damage and eventual rejection of the
transplanted tissue.

TNFa and LT are two closely related cytokines which are endogenous
mediators of immunological and inflammatory events. TNFa and LT share 36%
and 51 % structural homology in overall nucleotide and amino acid sequences,
respectively (Pennica et al., 1984), appear to have common receptor binding
domains (Aggarwal et al., 1985a), and also exert similar immunological effects in

vitro (Beutler & Cerami, 1986; Beutler, 1990). With regard to transplant
rejection, elevated levels of TNFa have been reported during rejection of rat
cardiac allografts (Lowry & Blais, 1988) as well as in human renal and liver
allografts (Maury & Teppo, 1987; Imagawa et al., 1990a). Additionally, enhanced
cytotoxic activity, attributed to LT, has been reported during renal allograft
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rejection (Hancock et al., 1991; Moy & Rosenau, 1981). We have recently
demonstrated elevated biphasic patterns for both TNFa and LT gene expression
post-tx in rat cardiac allografts (Pizarro et al., 1993a). This allospecific increase in
TNF levels noted within the first few days post-tx may act as an early indicator of
graft rejection. Furthermore, recent studies have reported successful use of antiTNFa and LT antibodies in prolonging the survival of transplanted grafts in
experimental animals, indicating a contribution of TNF in mediating acute
rejection (lmagawa et al., 1990b; Scheringa et al., 1991; Teramoto et al., 1991).
These data strongly suggest a role for TNFa and/or LT as putative effector
molecules in allograft rejection.

Cytotoxic T lymphocytes are believed to be important effector cells in the
destruction of transplanted tissue during allograft rejection (Loveland &
McKenzie, 1982; Lowry et al., 1983). Cytotoxic T cells recognize alloantigens on
the surface of MHC-nonidentical target cells, bind to them, and induce target cell
lysis (Hall et al., 1978). Although various steps in this process have been
analyzed in considerable detail, most studies have not provided insight into the
mechanism(s) by which the killer cell administers the "lethal hit" to the target cell.
Recently, two genes encoding the serine esterases HF and Cl 1 (Granzymes A and
B, respectively), which are selectively expressed in cytotoxic cells including
cytotoxic T lymphocytes and NK cells, have been cloned (Gershenfeld &
Weissman, 1986; Lobe et al., 1986). The kinetics of HF and C11 gene expression
closely parallel the cytolytic responses in vitro (Gershenfeld & Weissman, 1986;
Lobe et al., 1986), in that the observed kinetics of serine esterase release and of the
delivery of the lethal hit are consistent with the hypothesis that both events occur
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simultaneously. There exists, therefore, a strong correlation between granzyme
gene expression and cytotoxic potential. Detection of transcripts encoding
cytotoxic T cell serine proteases have been recently described in situ during
murine cardiac allograft rejection (Mueller et al., 1988). These data would
therefore suggest that cytotoxic cell-specific serine proteases, HF and Cl 1, may
play a role in the pathogenesis of rat cardiac allograft rejection.

The objectives of this study were to assess the degree of expression of the
genes encoding the serine proteases, HF and Cll, during rat cardiac allograft
rejection and to determine the effects of a combination low dose CSA/MTX
therapy on the expression of TNFa and LT, as well as HF and Cll, during
rejection. We report herein that combination low dose CSA/MTX
immunosuppressive treatment of rat cardiac recipients significantly decreases
TNFa, LT, HF, and Cll gene expression on days 1 through 8 post-tx in
transplanted allografts when compared to allografts retrieved from untreated
control recipients. Therefore, low dose CSA/MTX therapy prolongs cardiac
transplant survival and appears to act at the transcriptional level to
downregulate cytotoxic cytokine gene expression. Studies of cytotoxic cytokine
gene expression during allograft rejection may aid in the development of more
specifically targeted immunosuppressive therapies designed to prolong graft
survival.
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Materials and Methods

Animals
Pregnant BN and Lewis, and 6 to 8-week-old male Lewis rats were
purchased from Harlan Sprague Dawley (Harlan Sprague Dawley, Indianapolis,
IN). All animals received water and food ad libitum, and were housed in
accordance with institutional animal care and use guidelines. Adult male Lewis
rats served as recipients of donor cardiac tissue obtained from either 1 to 3 dayold Lewis or BN rats, which served as isograft and allograft groups, respectively.
The donor ages used have been previously reported to result in optimum isograft
viability (Fulmer et al., 1963) and were of appropriate size so that whole heart
grafts might be accommodated by the recipients' ears.
Cardiac Transplantation
The procedure utilized was a modification of the heterotopic method of
cardiac transplantation into the mouse ear as described by Fulmer et al (1963)
(Figure 6). Cardiac graft recipients were anesthetized with an i.p. injection of
ketamine/xylazine (20:1) (Fort Dodge Laboratories, Fort Dodge, IA and Rugby
Laboratories, Inc., Rockville Centre, NY) at 105 mg/kg body weight prior to
surgery. The dorsal surface of the recipient's ear pinna was nicked at the
proximal end with a sterile scalpel and a subcutaneous pouch was prepared
using blunt forceps. Whole newborn hearts were harvested promptly at the time
of donor sacrifice and gently inserted into the ear pouches of the recipients. In
order to prevent graft loss and promote revascularization, skin flaps surrounding
the graft site were apposed by applying gentle pressure with forceps. Each
recipient was grafted bilaterally, one whole heart per recipient ear, with either
two isografts or allografts per animal. Cardiac graft recipients were anesthetized
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and monitored daily by visual inspection for pulsatile activity and by
electrocardiography using pin electrodes placed on either side of the graft with
leads connected to a polygraph recorder (Grass Model 79D, Grass Instruments
Co., Quincy, MA) (Figure 7).
Animal Treatment Groups
Lewis cardiac allograft recipients were injected i.p. with CSA in olive oil
vehicle once daily, beginning on the same day of transplantation, and/or MTX in
saline vehicle once weekly, beginning 1 week prior to the day of transplantation
(day 0), as follows. Allograft recipients were placed in one of five treatment
groups consisting of either high dose CSA (15 mg/kg/ day), low dose CSA (1
mg/kg/ day), low dose MTX (450 µg/kg/wk), combination low dose CSA/MTX
treatment (1 mg/kg/ day and 450 µg/kg/wk, respectively), or control treatment
group (saline and olive oil vehicles according to the aforementioned protocol).
All allograft recipients received treatment through day 7 post-tx. Cardiac
transplants were monitored daily for pulsatile and ECG activity as described
above for graft survival, with retrieval of one graft per recipient occurring on
days 1-8 post-tx for each treatment group; cardiac grafts were processed for RNA
blot analysis as described below. Subsequent to these studies, a second treatment
group consisting of low dose CSA/MTX combination therapy was prepared to
permit graft retrieval at eight time points, days 1-8 post-tx.
Cell Culture
All cells were cultured in RPMI-1640 media supplemented with penicillinstreptomycin (100 U/ml and 100 µg/ml, respectively), 2 mM L-glutamine and
5% fetal bovine serum (GIBCO, Grand Island, NY) at a cell density of 1 X 106
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cells/ml at 37°C in 5% C02J with the exception of the RNK-16 cell line which was
also supplemented with 1% nonessential amino acids and 5 X 10-5 M 2-~mercaptoethanol (GIBCO). The murine macrophage cell line, ANA-1 (a gift from
Dr. Luigi Varesio, NIH, Frederick, MD), was incubated for 4 hr with 10 µg/ml
LPS (Difeo, Detroit, MI), and used as a positive TNFa mRNA control. The rat
NK cell line, RNK-16 (a gift from Dr. C.W. Reynolds, NIH, Frederick, MD), was
cultured for 18 hr in the presence of 20 ng/ml PMA and 1000 U /ml IL-2, (Sigma
Chemical Co., St. Louis, MO), and used as a negative TNFa mRNA control.
SMNCs isolated from adult male Lewis rats as described previously (Pizarro et

al., 1993a), were cultured for 18 hr with or without a combination of 20 ng/ml
PMA and 2 µg/ml PHA, and used as positive and negative controls, respectively,
for LT and granzyme mRNA expression. After incubation with respective
mitogens, cells were collected and processed for RNA as described below.
RNA Blot Analysis
For Northern and slot blot analysis, total cellular RNA was prepared
from cells and tissues by acid guanidinium thiocyanate-phenol-chloroform
extraction (Chomczynski & Sacchi, 1987), and blots were prepared as described
previously (Pizarro et al., 1993a). Filters were hybridized overnight at 42°C in a
solution containing either a TNFa cDNA probe prepared using the 1.7 kb murine
TNFa sequence cloned into the Pstl/BamHI site of pUC9 vector, (a gift from the
Chiron Corp., Emeryville, CA) (Pennica et al., 1985), an LT probe prepared using
a 0.71kb Kpnl/Hincll insert of the 1.42 kb murine LT cDNA fragment cloned into
the EcoRI/BamHI site of pBR322 vector (a gift from Dr. N. Ruddle, Yale
University, New Haven, CT) (Li et al., 1987), an HF probe synthesized from a 950
b.p. murine HF cDNA fragment cloned into the EcoRI site of pBS KS- vector (a
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gift from Dr. I. Weissman, Stanford University School of Medicine, Palo Alto,
CA) (Gershenfeld & Weissman, 1986), or a murine Cll probe prepared using an
800 b.p. Cl 1 cDNA sequence cloned into the EcoRI/BamHl site of pGEM3Z
vector (a gift from Dr. R.C. Bleackley, University of Alberta, Edmonton, ALB)
(Lobe et al., 1986), and prepared for autoradiography as described in an earlier
report (Pizarro et al., 1993a). Relative quantitation of mRNA signals on slot blot
autoradiographs were measured by transmission densitometry (Model EC910, EC Apparatus, Corp., St. Petersburg, FL) and reported as arbitrary units
representing integrated areas of densitometric tracings.

Protein Assays
Cardiac graft tissue homogenates were prepared using a Brinkmann
polytron (Brinkmann Instruments, Inc.) in 1.5 ml phosphate buffered saline
containing 2 mM PMSF protease inhibitor (Sigma Chemical Co.) for analysis of
TNF protein. Tissue homogenates were briefly centrifuged in a microcentrifuge
to remove excess particulate matter. Supernatants were then concentrated
approximately 10-fold using Centricon-10 microconcentrators (Amicon, Beverly,
MA). The samples were kept on ice for the duration of the assay and
subsequently stored at -70° C. Total protein levels were quantitated using a
modification of the Lowry colorimetric procedure (Sigma Diagnostics, St. Louis,
MO). Tissue samples were standardized to 150 µg total protein per well and
assayed in duplicate for TNF immunoreactive protein in an ELISA system using
a hamster anti-mouse TNF antibody (Genzyme Corp., Boston, MA), which
recognizes both mouse TNFa and LT. Results were analyzed
spectrophotometrically using a MR600 microplate reader (Dynatech
Laboratories, Inc., Chantilly, VA) and TNF levels were expressed as pg/ml and
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U /ml± SEM, relative to a recombinant mouse TNFa standard (Genzyme Corp.,
Boston MA).
Statistical Analysis
Experimental groups were compared using analysis of variance and
multiple regression analysis for the existence of significant differences between
treatment and control groups. Differences were considered to be statistically
significant at p ~ 0.05.
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Results
Cardiac allograft tissues were serially monitored for ECG and pulsatile
activity in order to determine graft viability post-tx. Allograft rejection was
defined by the absence of detectable ECG activity. The average time to allograft
rejection of cardiac transplants in untreated control recipients was determined to
be Day 7.4 ± 0.68 post-tx, with absence of detectable ECG and pulsatile activity
noted in all untreated control allografts by Day 10 post-tx (Pizarro et al., 1993a;
Pizarro et al., 1993b ).

Combination low dose CSA/MTX-treated recipients demonstrated a two
and one-half fold increase in survival time post-tx of transplanted cardiac
allografts when compared to cardiac allografts transplanted into untreated
control recipients (p ~ 0.01) (Pizarro et al, 1993b ). Cardiac transplants in low dose
CSA alone-treated recipients also demonstrated a less, but significant increase in
allograft survival time when compared to control (p ~0.05), while no statistically
significant difference in cardiac allograft survival times post-tx between MTXalone and untreated recipient groups were found (Pizarro et al., 1993b). Cardiac
allograft survival time post-tx in high dose CSA-treated recipients represented
the longest survival time of the four treatment groups; however, the incidence of
anesthesia-related death was increased in this experimental group (Pizarro et al.,
1993b).

Expression of the cytotoxic cytokine genes, TNFa and LT, was examined
in cardiac allografts transplanted into untreated control and combination low
dose CSA/MTX-treated recipients on days 1 through 8 post-tx. As shown in
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Figure 16, cardiac graft tissues were analyzed for the presence of TNFa mRNA
by Northern blot analysis. Expression of TNFa in cardiac allografts from
untreated control recipients appeared to be biphasic (Figure 16A). Peak levels of
TNFa mRNA appeared on day 3 post-tx, and although levels decreased by day 4
post-tx, an increase in TNFa mRNA appeared again on day 6 (5/10) or 7 (3/10)
post-tx, coinciding with graft rejection as measured by ECG activity. TNFa
transcript levels appeared to be significantly decreased in allograft heart tissues
from combination low dose CSA/MTX-treated recipients when compared to
untreated recipients on all days assayed post-tx (Figure 16B). Although TNFa
transcript levels were significantly decreased in cardiac allografts from
CSA/MTX-treated animals, these samples also indicated a biphasic pattern of
TNFa expression with time post-tx. Similar to untreated control allografts, an
increase in TNFa transcripts was detected on day 3 post-tx, and again just prior
to rejection in low dose CSA/MTX-treated allografts (Figure 16B). TNFa
transcript levels were undetectable in cardiac isografts on days 1-8 post-tx
(Pizarro et al., 1993a).
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Fig. 16A. TNFa mRNA levels in cardiac allografts transplanted into untreated
control recipients. Total RNA isolated from cardiac allografts retrieved on days
1-8 post-tx were examined by Northern blot analysis for TNFa gene expression.
A Representative Northern blot is shown above. As with Fig. 16 B, the murine
monocyte cell line, ANA-1, stimulated in vitro with LPS (10 µg/ml) for 4 hr was
used as a positive TNFa mRNA control, while the rat NK cell line, RNK-16,
stimulated in vitro with a PMA (20 ng/ml)/IL-2 (l000U/ml) combination served
as a negative control for TNFa mRNA expression. Kb, kilobases.
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Fig. 16B. TNFa mRNA levels in cardiac allografts transplanted into low dose
CSA/MTX-treated recipients. Total RNA isolated from cardiac allografts on
days 1-8 post-tx were examined by Northern blot analysis for TNFa gene
expression. Representative Northern blot is shown above. As with Fig. 16A,
blots were prepared using 15 µg of total RNA per lane; autogradiogram exposure
time was 18 hr. Ethidium bromide staining of 18S and 28S ribosomal RNA
subunits is included to illustrate standardized lane loading and intact, non
degraded cellular RNA.
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Fig. 17A. LT mRNA levels in cardiac allografts transplanted into untreated
control recipients. Total RNA isolated from cardiac allografts retrieved on days
1-8 post-tx were examined by Northern blot analysis for LT gene expression.
Representative Northern blot is shown above. As with Fig. 17B, SMNCs isolated
from adult male Lewis rats and stimulated in vitro with a combination of PMA
(20 ng/ml) and PHA (2 µg/ml) for 18 hr were used as a positive control, and
untreated SMNCs were used as a negative control for LT mRNA expression.
SMNCs, spleen mononuclear cells; Kb, kilobases.
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Fig. 17B. LT mRNA levels in cardiac allografts transplanted into low dose
CSA/MTX-treated recipients. Total RNA isolated from cardiac allografts
retrieved on days 1-8 post-tx were examined by Northern blot analysis for LT
gene expression. Representative Northern blot is shown above. As with Fig.
17A, blots were prepared using 15 µg of total RNA per lane; autogradiogram
exposure time was 5 days. Ethidium bromide staining of 18S and 28S ribosomal
RNA subunits is included to illustrate standardized lane loading and intact, non
degraded cellular RNA.
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Cardiac allograft transplants from untreated and low dose CSA/MTXtreated recipients were also analyzed for LT mRNA levels on days 1 through 8
post-tx by Northern blot analysis (Figure 17). Similar to TNFa, LT demonstrated
a biphasic pattern of gene expression in allografted heart transplants from
untreated recipients (Figure 17A). Peak levels of LT mRNA in untreated cardiac
allografts were observed on day 3 post-tx, with a second increase in LT transcript
levels occurring later, coincident with graft rejection. In contrast, LT mRNA
levels were significantly reduced in low dose CSA/MTX-treated cardiac
allografts when compared to untreated controls (Figure 17B); low to undetectable
levels of LT transcripts were found in low dose CSA/MTX-treated allografts on
Days 1 through 8 post-tx (Figure 17B). Similar patterns of TNFa and LT mRNA
levels were observed in slot blot analysis (Figure 18A and 18B), where all cardiac
allograft RNA samples were exposed to identical hybridization and
autoradiography conditions, with different exposure times. LT mRNA levels
were undetectable in cardiac isografts on days 1-8 post-tx (Pizarro 1993a).
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Fig. 18. Densitometric measurement of TNFa and LT transcript levels from
representative slot blots of cardiac allograft total cellular RNA. mRNA levels for
TNFa (A) and LT (B) are expressed as arbitrary units representing integrated
areas of densitometric tracings obtained by transmission densitometry. Slot blots
were prepared by loading 8 µg total RNA of sample per slot; autoradiogram
exposure time was 1 day for TNFa and 3 days for LT.

In order to determine whether TNF protein levels paralleled the
observed changes in mRNA, an ELISA method using an antibody which
recognizes both murine TNFa and LT was used to quantitate TNF protein in
transplanted cardiac tissues from untreated and low dose CSA/MTX-treated
recipients. TNF protein levels in cardiac allografts from untreated recipients as a
group were significantly increased over cardiac allografts in low dose
CSA/MTX-treated recipients (p .s. 0.001) (Figure 19). TNF protein from untreated
allografts demonstrated a biphasic pattern, similar to that shown for TNFa and
LT mRNA from cardiac allograft tissues in untreated recipients. Two and onehalf-fold greater levels of TNF were measured in untreated allografts
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(approximately 400 pg/ml or 16.5 U /ml; 1 U = approx. 24.3 pg) compared to low
dose CSA/MTX-treated allografts on day 3 post-tx (p ~ 0.001). A second increase
in TNF levels appeared in untreated allografts on day 6 post-tx, coincident with
allograft rejection, as measured by the absence of ECG activity. TNF protein
levels in cardiac allografts in combination low dose CSA/MTX-treated recipients
did not vary significantly, measuring approximately 150 pg/ml or 6.0 U /ml at all
time points examined post-tx (Figure 19). In contrast to TNF protein levels
measured in cardiac allografts, TNF levels in cardiac isografts were at or below
standard limits of detection (50 pg/ml) at all times except day 3 (100 pg/ml)
post-tx (Pizarro et al., 1993a), and were significantly decreased compared with
time-matched cardiac allografts from either control-untreated (p ~ 0.001) or low
dose CSA/MTX-treated (p ~ 0.01) recipients.

Expression of granzymes A and B, HF and Cl1, respectively, were
examined in cardiac transplants at various times post-tx. Cardiac transplants
from untreated allograft recipients were analyzed for the presence of HF (Figure
20A, top panel) and Cl 1 (Figure 20A, middle panel) on days 1 through 8 post-tx

by Northern blot analysis. Expression of HF and C11 mRNA occurred at later
time points during the rejection process compared to TNFa and LT. Granzyme
A and B transcripts were detected on days 5 through 7 and days 5 and 6 post-tx,
respectively, in cardiac transplants from untreated allograft recipients (Figure
20A). Granzyme mRNA levels were therefore elevated just prior to allograft

rejection, with HF and Cl 1 transcript levels undetectable at earlier time points
post-tx.
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Fig. 19. TNF protein levels in cardiac transplants from low dose CSA/MTXtreated and untreated control recipients. Cardiac allograft tissues were retrieved
on days 1 through 8 post-tx and analyzed for TNF protein, expressed as pg/ ml
and U/ml (1 U = approx. 24.3 pg)± S.E.M. Data shown are mean values± S.E.M.
of four experiments performed with different allograft tissue samples (p ~ 0.001).

Cardiac allografts from combination low dose CSA/MTX-treated
recipients were also analyzed on days 1 through 8 post-tx by Northern blot
analysis for HF and Cl 1 mRNA levels. Transcript levels for both HF and Cl 1
were undetectable in allografts from low dose CSA/MTX-treated recipients on
all days assayed post-tx (Figure 20B and 20C, respectively). Furthermore, no
detectable levels of HF or Cll transcripts were found on days 1 through 10 posttx in RNA samples prepared from cardiac isografts (Figure 20D). When cardiac
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allograft samples from untreated and low dose CSA/MTX-treated recipients
were assayed simultaneously and compared by slot blot analysis, HF (Figure
21A) and Cll (Figure 21B) mRNA levels were detected only in tissue from
untreated recipients, at times and levels similar to those demonstrated in
Northern blot analysis (Figures 20A).
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Fig. 20A. HF and Cll mRNA levels in cardiac allografts transplanted into
untreated control recipients. Total RNA isolated from cardiac allografts retrieved
on days 1-8 post-tx were examined by Northern blot analysis for HF (top panel)
and Cll (middle panel) gene expression. A representative Northern blot is
shown above. As with Fig. 20B, 20C, and 20D, blots were prepared using 15 µg
of total RNA per lane; autogradiogram exposure time was 2 days for both HF
and Cll probes. Ethidium bromide staining of 18S and 28S ribosomal RNA
subunits (bottom panel) is included to illustrate uniformity of lane loading and
intact, nondegraded cellular RNA. Kb, kilobases.
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Fig. 20B. HF mRNA levels in cardiac allografts transplanted into low dose
CSA/MIX-treated recipients. Total RNA isolated from cardiac allografts
retrieved on days 1-8 post-tx were. examined by Northern blot analysis for HF
gene expression. Representative Northern blot is shown above.
Autogradiogram exposure time was 5 days.
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Fig. 20C. Cl 1 mRNA levels in cardiac allografts transplanted into low dose
CSA/MTX-treated recipients. Total RNA isolated from cardiac allografts
retrieved on days 1-8 post-tx were examined by Northern blot analysis for Cll
gene expression. Representative Northern blot is shown above. Representative
Northern blot is shown above. Autogradiogram exposure time was 5 days.
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Fig. 21. Densitometric measurement of HF and C11 transcript levels from
representative slot blots of cardiac allograft total cellular RNA. mRNA levels for
HF (21A) and C11 (21B) are expressed as arbitrary units representing integrated
areas of densitometric tracings obtained by transmission densitometry. Slot blots
were prepared by loading 8 µg total RNA of sample per slot; autoradiogram
exposure time was 3 days for both HF and C11 probes.
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Fig. 20D. HF and C11 mRNA levels in cardiac isografts transplanted into
untreated control recipients. Total RNA isolated from cardiac isografts retrieved
on days 1-7 and 10 post-tx were examined by Northern blot analysis for HF (top
panel) and Cl 1 (middle panel) gene expression. Representative Northern blots
are shown above. Autogradiogram exposure time was 5 days for both HF and
Cll probes.
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Discussion
Using a heterotopic method of cardiac transplantation into the rat ear, we
have previously reported that treatment of cardiac transplant recipients with
combination low dose CSA/MTX immunosuppressive therapy resulted in
allograft survival times which more than doubled when compared to survival of
allografts transplanted into untreated control recipients (p ~ 0.01) (Pizarro et al.,
1993b). The average time to rejection of untreated control allografts was
previously found to be Day 7 post-tx (Pizarro et al., 1993a), whereas combination
low dose CSA/MTX-treated recipients undergo acute rejection by day 18 post-tx,
at which time ECG and pulsatile activity was virtually undetectable (Pizarro et
al., 1993b). In addition, combination low dose CSA/MTX treatment increased

graft survival over cardiac allografts transplanted in either low dose CSA or MTX
alone-treated recipients (Pizarro et al., 1993b ).

In order to elucidate the possible mechanism(s) by which combination low
dose CSA/MTX prolongs rat cardiac allograft survival, we have previously
examined IL-2 production at the mRNA level (Pizarro et al., 1993b). IL-2 mRNA
levels were examined in cardiac allografts to determine if low dose CSA/MTX
therapy, like high dose CSA treatment, exerted its immunosuppressive action
through inhibition of IL-2 gene expression. IL-2 appears to be an important
mediator of allograft rejection since a positive correlation between IL-2 levels and
rejection episodes has been described (Yoshimura & Kahan, 1985; McKenna et
al., 1988). CSA is believed to exert its immunosuppressive actions through potent

inhibition of IL-2 production by T cells (Kronke et al., 1984; Elliot et al., 1984). We
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found that, in contrast to high dose CSA administration, combination low dose
CSA/MTX treatment (1.0 mg/kg/day and 450 µg/kg/week, respectively) did
not alter IL-2 gene expression. Similar patterns of IL-2 gene expression were
found in cardiac allografts from both low dose CSA/MTX-treated and untreated
transplant recipients on days 1 through 8 post-tx (Pizarro et al., 1993b).
Therefore, cardiac allografts in both low dose CSA/MTX-treated and untreated
control recipients indicated comparable increases in IL-2 mRNA levels. Unlike
high dose CSA treatment, the mechanism(s) by which low dose CSA/MTX
combination therapy increases allograft survival time post-tx does not appear to
be mediated by the inhibition of IL-2 gene expression.

We, and others, have reported the presence of elevated levels of TNFa and
LT during allograft rejection (Pizarro et al., 1993a; Lowry & Blais, 1988; Moy &
Rosenau, 1981). Importantly, results of anti-TNFa and LT antibody therapy
increasing allograft survival time imply that TNF is a mediator of acute rejection
(Imagawa et al., 1990b; Scheringa et al., 1991; Teramoto et al., 1991). Taken
together, these data strongly suggest a role for TNFa and/or LT in the
pathogenesis of allograft rejection. We therefore chose to investigate the effects
that combination low dose CSA/MTX therapy might have on the expression of
these cytotoxic cytokines.

In the present study, rat cardiac allografts transplanted into combination
low dose CSA/MTX-treated recipients indicate significant decreases in TNFa
and LT mRNA and protein levels between days 1 through 8 post-tx when
compared to untreated allograft controls. Although TNFa transcript levels were
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significantly decreased in cardiac allografts from CSA/MTX-treated animals, low
dose CSA/MTX treatment did not abrogate TNFa gene transcription. Low but
detectable levels of TNFa mRNA were seen on day 3 post-tx, and again on days 7
or 8 post-tx with combination treatment, similar to the pattern in control
allografts from untreated recipients. In contrast to TNFa gene expression, LT
mRNA levels in cardiac allograft transplants from low dose CSA/MTX-treated
recipients were virtually undetectable on days 1 through 8 post-tx.

TNF protein levels in cardiac allografts transplanted into untreated
recipients were significantly increased over cardiac allografts from low dose
CSA/MTX-treated recipients (p 5. 0.001). TNF protein in allografts from
untreated recipients demonstrated a biphasic pattern, similar to that shown for
TNFa and LT mRNA, while TNF protein levels in transplants from low dose
CSA/MTX-treated recipients remained low and did not significantly fluctuate on
days 1 through 8 post-tx. In contrast to cardiac allografts transplanted into either
control or low dose CSA/MTX-treated recipients, TNF protein levels in timematched cardiac transplants from isograft recipients have been shown to be at or
below standard limits of detection on all measured time points except day 3 posttx (Pizarro et al., 1993a). Therefore, TNF protein levels in cardiac isografts were
found to be significantly decreased when compared to cardiac allografts from
either control or low dose CSA/MTX treated recipients, indicating that TNF
expression appears to be allograft specific.

In addition to TNFa and LT levels, expression of granzymes A and B was
also examined in cardiac transplants. The HF (granzyme A) gene encodes a
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trypsin-like serine esterase, while Cll (granzyme B) encodes a chymotrypsin-like
serine protease with apparent specificity for acidic residues (Lobe et al., 1986).
The HF protein is promptly secreted by both cytotoxic CD4 + and CDS+ T cells
and NK cells after stimulation in vitro, while Cll has been detected in activated
cytotoxic T lymphocytes and NK cells (Velotti et al., 1989; Griffiths & Mueller,
1991a). Granzymes are considered to be essential mediators in cell-mediated
cytolysis by both cytotoxic T cells and NK cells, and it has been postulated that
they may serve as diagnostic markers for cardiac allograft rejection (Griffiths et
al., 1991b ).

In the present study we report that expression of HF and Cl 1 occurs at
later times during rejection compared to TNF. Granzyme mRNA levels were
elevated just prior to allograft rejection, with HF or Cll transcript levels
undetectable at earlier time points post-tx. Granzyme mRNA levels in cardiac
allografts from combination low dose CSA/MTX-treated recipients were
undetectable in low dose CSA/MTX-treated allografts on all days assayed posttx. Furthermore, no detectable levels of either HF or Cl 1 transcripts were found
in day-matched cardiac isografts. Therefore, although granzymes may be
indicators of rat cardiac allograft rejection, TNFs may serve as important early
marker of cardiac allograft rejection.

The present study reports a decreased expression of the cytotoxic
cytokines TNFa and LT, and granzymes A and B, (HF and Cll), in cardiac
allografts transplanted into low dose CSA/MTX-treated recipients when
compared to untreated recipients. The actual functional significance of
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combination low dose CSA/MTX treatment, however, is less well understood. It
has been demonstrated that low dose CSA therapy (2.0 mg/kg/ day) of allograft
recipients reduces T cell proliferative responsiveness, but is unable to sustain
long-term cardiac allograft survival (Stepkowski et al., 1989). The possibility
exists that low dose CSA may also affect TNFa production from T lymphocytes
since activated peripheral T cells have been shown to be a contributing source of
TNFa (Steffen et al., 1988). In addition, the immunosuppressive effect of low
dose CSA may not be limited to T lymphocytes; in fact, low dose CSA treatment
(1.0 µg/ml) has been described to also affect monocyte cell function in vitro by
inhibiting IL-la and ~, as well as PGE2 production (Reisman et al., 1991).
However, in vivo, different populations of human monocytes have been reported
to possess varying sensitivities to CSA (Esa et al., 1988). The possibility therefore
exists that low dose CSA may affect production of TNF as well as IL-2.

Low dose CSA therapy, while prolonging cardiac allograft survival, does
not have the efficacy of combination low dose CSA/MTX. In addition, the
mechanism(s) by which MTX appears to exert immunosuppression is still poorly
understood, it is believed that MTX possesses primarily anti-inflammatory
activity (Weinblatt et al., 1985). Direct evidence of MTX immunomodulation is
supported by reports describing the effects of MTX in experimental models of
arthritis, in which the production of IL-1 and induction of primary delayed-type
hypersensitivity were inhibited in MTX-treated rats (Hu et al., 1988; O'Callaghan

et al., 1986).
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The present study explores the mechanism of action of combination low
dose CSA/MTX therapy in prolonging cardiac allograft survival. The possibility
exists that low dose CSA/MTX combination therapy may act on two different
effector cells of the immune response, i.e., cytotoxic T cells and macrophages, by
inhibiting production of immune mediators, such as granzymes and TNF. The
present study also supports a role for the cytotoxic cytokines, TNFa and LT, and
granzymes A and Bin the pathogenesis of allograft rejection. Experiments are
currently underway in our laboratory to examine levels of these cytotoxic gene
products just prior to rejection time in combination low dose CSA/MTX treated
recipients of cardiac allografts. Studies such as these are designed to elucidate
the pathophysiological mechanisms involved in graft rejection and may lead to
more effective immunosuppressive therapy using synergistic combination
treatments aimed at promoting graft survival while minimizing adverse side
effects.
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CHAPTERV
SUMMARY

One of the major problems associated with cardiac transplantation is
rejection of the allografted heart. The immune response to alloantigen involves
the production of, by different cell types, soluble endogenous mediators, which
include cytokines and granzymes. The present dissertation has investigated
possible pathophysiological mechanisms involved in cardiac allograft rejection
by examining the production of these cytotoxic mediators in a heterotopic model
of rat cardiac transplantation. In particular, detection and quantitation of the
cytotoxic products TNFa, LT, HF, and Cl1, were measured during the process of
cardiac allograft rejection. Identification of which cytotoxic mediators are
present during the course of rejection, and when post-tx, may aid in designing
more specifically targeted therapies aimed to promote graft success.

Additionally, success of the allografted heart is critically dependent on the
availability of powerful immunosuppressive agents that have the ability to
effectively prolong graft survival and prevent allograft rejection. Currently,
administration of potent immunosuppressive drugs to transplant recipients not
only dramatically increases the chances of allograft survival, but also with the
possibility of decreasing toxic side effects. An alternative approach to reduce
these side effects associated with high dose immunosuppression utilizes the
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administration of low dose combination therapies that may act synergistically to
inhibit alloactivation. Studies contained in this dissertation examined the use of
a low dose CSA/MTX combination therapy during cardiac transplantation.
Specifically, low dose CSA/MTX combination therapy was investigated in order
to determine its ability to prolong rat cardiac allograft survival. In addition,
modulation of the cytotoxic mediators, TNFa, LT, HF, and Cll, was measured in
cardiac allografts obtained from low dose CSA/MTX-treated recipients. Studies
such as these are designed to improve allograft success by administrating
synergistic combination therapies which prolong graft suvival and minimize the
number of adverse side effects.

It has previously been shown that donor MHC-incompatible antigens
have the ability to precipitate a host allograft rejection response in small animal
models (McKenzie & Henning, 1977; Lowry et al., 1985a). Therefore, MHCincompatibility between transplant donor and recipient has become an
experimental parameter when investigating allograft rejection. The studies
contained within this dissertation employed a modification of a heterotopic
method of cardiac transplantation into the mouse ear, originally described by
Fulmer et al (1963), and applied it to a rat system as a model of allograft rejection
using the MHC-mismatched BN or DA donor hearts into Lewis recipients as
allograft pairs and Lewis donor hearts into Lewis recipients as isograft pairs.

The heterotopic transplantation of cardiac grafts into the rat ear provides
many advantages when investigating the processes of allograft rejection. Using
this method, cardiac graft recipients are subject to minimal trauma compared to
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those undergoing vascular transplantation techniques, and therefore have an
increased chance of survival. Furthermore, because of the ease of graft
placement and subsequent graft retrieval, it is possible to evaluate a large
number of animals for consistent trends characteristic of graft rejection.
Additionally, graft success is more conveniently monitored. Visual
transillumination of the recipients' ears is possible to determine size and
swelling, patterns of vascularization, and pulsatile activity of the cardiac grafts.
ECG recordings via direct placement of pin electrodes into the ear pinnae on
either side of the transplanted heart enables quantitative as well as qualitative
information when monitoring cardiac graft viability. ECG recordings taken from
heterotopically transplanted cardiac grafts into rat pinnae allow quantitative
comparative analyses between experimental groups, which may be problematic
in vascular-connected transplants due to the possible interference of the
recipient's own intrinsic heartbeat. In fact, using the heart into ear model, the
ability to distinguish between graft and recipient heart rate is easily determined.
Therefore, although a nonvascular method of cardiac transplantation into the rat
ear pinnae may not exactly parallel events occurring in human transplant
rejection, this model provides multiple advantages when examining the
pathogenic events leading to allograft rejection.

Using the rat heart into ear transplantation model, it was established that
cardiac allografts, but not isografts, undergo rejection by day 10 post-tx, at which
time ECG activity is undetectable. Additionally, the average day to rejection of
rat allografted hearts was determined to be 7 days post-tx, whereas isografted
hearts demonstrated regular ECG and pulsatile activity up to 18 months post-tx.
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These results are in accordance with a heterotopic method for accessory cervical
heart transplantation in rats using the same allograft and isograft pairings, which
has been subsequently established in our laboratory. Using this transplantation
method of direct vascular anastomoses, the average day to rejection of
allografted hearts was determined to be 8 days post-tx, while isografted hearts
displayed viability for at least one year post-tx (Payne et al., submitted). These
findings are also consistent with earlier reports by other investigators which
assessed rat cardiac allograft rejection by cessation of palpable pulsatile activity
(Tilney et al., 1978; Hancock et al., 1991; Scheringa et al., 1991). Taken together,
these data suggest that the rat heart into ear graft technique may provide a useful
model to investigate the mechanisms of allograft rejection in cardiac
transplantation.

Detection and quantitation of soluble endogenous mediators produced
during inflammatory processes in response to alloantigen were measured during
rat cardiac allograft rejection using the heart into ear model. The studies
contained within the present dissertation focused on the production of cytotoxic
mediators, including TNF and granzymes. Specifically, TNF -a and

~

(LT) were

examined for reasons mentioned earlier (Chapter 1), including their many
proinflammatory actions which may contribute to allograft rejection responses.
These effects include potent induction of chemotactic factors causing effector cell
infiltration, augmentation of class I MHC antigen expression, stimulation of
platelet activating factor (PAF) promoting ischemia within the graft, and
induction of macrophage activation (Reviewed in Halloran et al., 1989). In
addition, it had previously been shown that a strong correlation exists between
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granzyme gene expression and cytotoxic potential (Gershenfield & Weissman,
1986; Lobe et al., 1986). In fact, one of the first studies demonstrating their
importance involved the detection of granzyme-expressing lymphocytes in vivo
during murine cardiac allograft rejection (Mueller et al., 1988). For these reasons,
including those previously mentioned (Chapter 1), HF and Cll (granzymes A
and B) were measured, using the aforementioned heart into ear model, for their
putative role in the process of rat cardiac allograft rejection.

TNF and granzyme expression was examined in a window of time
consisting of days 1 through 8, and in some cases through day 10, post-tx. This
time frame was established based on the findings that using the rat heart into ear
graft technique, the average time to rejection of cardiac allografts was 7 days
post-tx, with no detectable ECG activity measured by day 10 post-tx. In fact,
both TNFa and LT mRNA and protein levels in cardiac allografts consistently
demonstrated a biphasic pattern of expression where peak levels were reached
on day 3 post-tx with a second increase on day 6 or 7 post-tx which subsequently
decreased through day 10 post-tx. In contrast to TNF expression found in
allografts, TNFa and LT mRNA transcripts were undetectable in isografts on
days 1 through 10 post-tx, while TNF protein levels were consistently
undetectable or significantly reduced when compared to time-matched
allografts. Therefore, these data indicate that increased expression of TNF
appears to be allograft-specific and occurs early during rat cardiac allograft
rejection, possibly serving as an important early indicator of transplant rejection.
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Compared to TNF, granzyme expression occurred at later time points
during the rejection process. Granzyme mRNA levels were elevated just prior to
rejection with HF and Cl 1 transcripts detected on days 5 through 7 and days 5
and 6 post-tx, respectively, in rat cardiac allografts. Furthermore, no detectable
levels of HF or Cl 1 transcripts were found on days 1 through 10 post-tx in rat
cardiac isografts. Taken together, these data suggest that although granzymes
may be indicators of rat cardiac allograft rejection, TNF may serve as an
important early marker of cardiac allograft rejection.

As mentioned earlier, the significance of the early rise in TNF (TNFa and
LT) levels post-tx is unknown. Although the second increase in TNF expression
appears to be solely allograft-specific, the first peak is noted in both allograft and
to a lesser extent, in isograft tissues. Speculation regarding this early elevation in
TNF gene expression may be, in part, due to postsurgical inflammatory
(nonallospecific) events. In addition, this significantly greater early TNF
response present in allografts may reflect allospecific events, including
endothelial cell activation (Collins et al., 1986) and augmented migration and
adhesion of leukocytes (Shalaby et al., 1985). Furthermore, since TNF is known to
have angiogenic properties, the possibility exists that an increase in TNF
production following transplantation may be due, in part, to the graft's need for
vascularization. One possible source of TNF may be activated mononuclear
phagocytes in the heart graft, since it has been reported that TNFa is released by
infiltrating macrophages which are present early in the rejection process (Lowry
& Blais, 1988; MacPherson & Christmas, 1984; Payne et al., submitted). Another

contributing source may be activated peripheral T lymphocytes, which have also
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been shown to synthesize TNF (Steffen et al., 1988). Therefore, results obtained
from the present studies indicate significant elevations in graft TNF levels well in
advance of transplant rejection.

The second increase in TNF levels observed in cardiac allografts appears
to coincide with the time of graft rejection. Although the actual roles of TNFa
and LT in rejection are not clearly defined, they may participate in the rejection
process by indirect activation of leukocyte subpopulations or by direct lytic
mechanisms of the graft parenchyma. The biphasic pattern of TNF expression
demonstrated in the present studies is also consistent with previous reports
demonstrating that rat cardiac allografts elicit a biphasic cellular immune
response, with the second phase coinciding with the time of acute graft rejection
(Tilney et al., 1978). More recent studies also showed similar trends of bimodal
TNF expression in the pathogenesis of rat lung allograft rejection, with
significant attenuation in those recipients pretreated with neutralizing TNF
antisera (DeMeester et al., 1993). Therefore, activated mononuclear leukocytes,
including macrophages, infiltrating the graft parenchyma may be responsible for
the early rise in TNF levels which subsequently may serve as an early marker of
incipient rejection, while the second increase in TNF levels is more coincident
with graft rejection and may represent an accumulation of events leading to
eventual tissue graft destruction.

These data are also supported by recent findings in our laboratory using a
heterotopic method for accessory cervical heart transplantation, wherein
immunohistochemical characterization of the cellular phenotypes present in
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rejecting rat cardiac allografts was performed (Payne et al., submitted). The
results from these studies demonstrated significantly elevated staining in cardiac
allografts for the macrophage/monocyte population as early as day 2 post-tx,
which remained sustained through day 8 post-tx. Moreover, macrophages
appeared to precede T cells in transplant infiltrates; immunohistologic staining
for the CDS+ T cell subset was markedly increased by day 4 post-tx and appeared
to be allograft-specific (Payne et al., submitted). This is consistent with the
expression of the granzymes, HF and Cll in the present dissertation which was
present between days 5 through 7 post-tx in cardiac allografts. Therefore, as
stated earlier, granzymes may indicate rejection, however, TNF appears to be an
earlier marker of rat cardiac allograft rejection.

Once the time course for TNF and granzyme elaboration was determined
in the rat heart into ear transplantation model, it appeared as though the crucial
window of time for studying TNF and granzyme expression was on days 1
through 8 post-tx. A low dose CSA/MTX combination immunosuppressive
therapy was then investigated as a possible approach to prolong allograft
survival and to examine how this treatment would modulate TNF and granzyme
expression. As stated earlier, low dose CSA/MTX treatment was considered as
an alternative immunosuppressive therapy to promote allograft survival while
minimizing high dose CSA side effects. Furthermore, immunosuppressive
effects have been attributed to MTX (Mitchell et al., 1969), which has shown some
success in the treatment of rheumatoid arthritis (Weinblatt et al., 1985; Perhala &
Wilke, 1991).
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The results from the present studies have indicated that low dose
CSA/MTX treatment significantly prolonged rat cardiac allograft survival over
day-matched allografts transplanted into untreated control recipients, where the
average day to rejection was day 18 and day 7 post-tx, respectively. Therefore,
treatment of cardiac allograft recipients with combination low dose CSA/MTX
therapy more than doubled allograft survival time post-tx when compared to
untreated controls. Combination low dose CSA/MTX therapy also significantly
increased graft survival compared to low dose CSA alone as well as MTX-alone
treated allograft recipients. High dose CSA-treated recipients had the longest
allograft survival time (36 days); however, high mortality was noted in this
treatment group following anesthesia administration during cardiac monitoring.
Although the reasons for this phenomenon are unknown, the possibility exists
that apparent complications may be due to known toxicities associated with high
dose CSA administration.

The mechanism(s) by which low dose CSA/MTX combination therapy
produces its effect is unknown. Low dose CSA treatment (1.0 mg/kg/day) of
allograft recipients has been shown to reduce T cell proliferative responsiveness
but was unable to sustain long-term cardiac graft survival (Stepkowski et al.,
1989). This suggests that low dose CSA has the ability to prolong cardiac graft
survival post-tx by activation of T cell suppressor function(s) and / or by altering
T cell proliferation. In fact, the present studies indicate that low dose CSA
treatment, while able to delay allograft rejection, does not have the efficacy of
combination low dose CSA/MTX in prolonging rat cardiac allograft survival.
Therefore, the possibility exists that MTX provides additional
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immunosuppressive capabilities by affecting T cell function and/ or regulating
other cells participating in the immune response.

Although it is unclear by which mechanism(s) MTX exerts its
immunosuppressive effects, animal studies support an anti-inflammatory mode
of action. In a murine model of adjuvant-induced arthritis, MTX has been
reported to inhibit hind paw edema, the activation of macrophages by PGE2, the
influx of MHC class II and macrophages into synovial tissue, and IL-1
production (Hu et al., 1988). These data support the possible role MTX may have
in inhibiting macrophage effector cell function. Therefore, in the present study,
significant prolongation of cardiac allografts transplanted into combination low
dose CSA/MTX-treated recipients may be due, in part, to the combined
immunosuppressive actions of low dose CSA primarily at the T cell level and
MTX primarily at the macrophages effector cell level.

IL-2 mRNA levels in transplanted cardiac tissues was also examined to
determine whether combination low dose CSA/MTX treatment, like high dose
CSA, exerts its immunosuppressive action by altering steady state levels of IL-2
mRNA. IL-2 gene transcripts were not detected in isografts or in allografts
transplanted into high dose CSA-treated recipients on any day post-tx when
compared to allografts from untreated recipients, supporting previous reports
demonstrating suppression of IL-2 gene transcription with high dose CSA
administration (Kronke et al., 1984 and Elliot et al., 1984). No apparent
differences in IL-2 mRNA transcript levels were observed, however, between
allografts transplanted into untreated and low dose CSA/MTX-treated
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recipients. IL-2 mRNA transcripts appeared early after transplant and remained
elevated through day 8 post-tx. Therefore, unlike high dose CSA therapy, the
mechanism(s) by which low dose CSA/MTX prolongs allograft survival does not
appear to be mediated by the inhibition of IL-2 gene transcription.

The effects of low dose CSA/MTX on the expression of the cytotoxic
mediators, TNFa, LT, and granzymes A and B (HF and Cll, respectively) were
then examined in an attempt to elucidate possible mechanism(s) by which low
dose CSA/MTX therapy increases the time of allograft survival. Significant
suppression of TNFa, LT, HF, and Cll gene expression was seen on days 1
through 8 post-tx in cardiac allografts from low dose CSA/MTX-treated
recipients compared to untreated allograft controls. TNF protein levels in cardiac
allografts from low dose CSA/MTX-treated recipients were also found to be
significantly reduced on days 1 through 8 post-tx when compared to timematched untreated allograft controls. This data indicate that low dose
CSA/MTX treatment is effective in prolonging rat cardiac transplant survival
and appears to act at the transcriptional level to downregulate cytotoxic gene
expression. Table 4 describes the studies contained within this dissertation by
summarizing the cytokine and granzyme levels in low dose CSA/MTX-treated
and untreated control cardiac grafts. Table 4 is a qualitative description
comparing relative levels of mediators among experimental groups; quantitative
measurements can not be extrapolated from this information.
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TABLE 4. Summary of cytokine levels in low dose CSA/MTX-treated and
untreated control cardiac grafts.

DAY POST-TX

TREATMENT
1

2

CSA/MTX

3

4

5

6

++

7

8

+

+

CYTOKINE
MEASURED

TNFa

ALLO.CONT.

++ ++

+ +++ +

mRNA

ISO.CONT.
CSA/MTX
LT

ALLO.CONT.

++

++-I

mRNA

ISO.CONT.
CSA/MTX

+ +++ ++

+

++

+

+

+

+

+

+

+

TNF

ALLO.CONT.

+

ISO.CONT.

+

+

protein

+

CSA/MTX
HF

ALLO.CONT.

+

+

+

+

+

mRNA

ISO.CONT.
CSA/MTX
Cll

ALLO.CONT.

mRNA

ISO.CONT.
CSA/MTX

+

+ +++ +++ 4-++ +++ ++-+ ft-+-+
IL-2

ALLO.CONT.

+

+ +++ ++-+ ft-++ +++ ++-+ ft-+-+

ISO.CONT.
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mRNA

The actual functional significance of combination low dose CSA/MTX
treatment is less well understood. As mentioned earlier, the possibility exists
that low dose CSA may affect T cell responsiveness (Stepkowski et al., 1989) as
well as TNF production from T lymphocytes since activated peripheral T cells
have also been shown to be a contributing source of TNFa (Steffen et al., 1988).
In the same manner, CSA may also have an effect on granzyme production since
granzymes have been shown to be primarily a T cell product. Additionally, as
stated earlier, the possibility exists that MTX may play a role in downregulating
macrophage effector cell function. Therefore, TNFa production by macrophages
may be affected by MTX administration. In the present studies, significant
prolongation of cardiac allografts transplanted into combination low dose
CSA/MTX-treated recipients may be due to combined immunosuppressive
actions of both low dose CSA and MTX, acting on both T cells and macrophage
effector cells.

Alternatively, the combination of low dose CSA plus low dose MTX may
act in a synergistic manner. Further studies are needed to examine the effects of
both low dose CSA alone and low dose MTX alone treatment on the
aforementioned cytotoxic mediators in order to determine if a single
immunosuppressive agent is regulating a specific cytokine or if the combination
low dose CSA/MTX is acting synergistically. In addition, it would be interesting
to perform dose-response experiments in which the dose of each individual
immunosuppressive agent (CSA or MTX) would vary, and their effect on each
cytotoxic mediator measured. In this way, an ideal dosage of each
immunosuppressive drug can be established to downregulate a specific cytotoxic

130

mediator. Furthermore, an optimal dosage of combination CSA/MTX which
elicits the greatest decrease in one or more mediators may be determined.

The studies contained within this dissertation have explored the
possibility of using combination low dose immunosuppressive therapy,
specifically low dose CSA/MTX, as an alternative treatment aimed at prolonging
rat cardiac graft survival while minimizing adverse side effects often associated
with use of high dose immunosuppression following allograft transplantation.
Low dose CSA/MTX combination treatment has been shown to decrease the
expression of the cytotoxic mediators TNFa, LT, HF, and Cll during allograft
rejection. Figure 22 summarizes the postulated effects that low dose CSA/MTX
combination therapy may have on TNF and granzyme production during rat
cardiac allograft rejection.

The need remains for CSA, MTX, and other immunosuppressive drugs to
be evaluated for their efficacy in downregulating TNFa, LT, HF, C11, and other
proinflammatory mediators involved in allograft rejection. Insight into which
cytotoxic mediators are synthesized, and when post-tx they appear, may provide
opportunities for early detection of molecular "markers" that signal impending
rejection. Assessment of the cytokine profile during allograft rejection may also
aid in the development of more specifically targeted immunosuppressive
therapies designed to prolong graft survival.
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Fig. 22. Postulated effects of low dose CSA/MTX administration on TNF and
granzyme production during rat cardiac allograft rejection.
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